
MFT TRUST FORMULARY



	BNF Chapter
Section 1:	Gastro-Intestinal System
Section 2:	Cardiovascular System
Section 3:	Respiratory System
Section 4:	Central Nervous System
Section 5:	Infections
Section 6:	Endocrine System
Section 7:	Obstetrics, gynaecology & urinary tract disorders
Section 8:	Malignant disease & immunosuppression
Section 9:	Nutrition & blood
Section 10:	Musculoskeletal & Joint Diseases
Section 11:	Eye
Section 12:	Ear, nose & oropharynx
Section 13:	Skin
Section 14:	Immunological products & vaccines
Section 15:	Anaesthesia
Section 16:	Miscellaneous

Version 10.6 (June 2025)



Prescribers must always bear in mind when prescribing medicines recommended as "treatment options" by NICE, that this is an opportunity for the clinician and the patient to consider and discuss its use alongside other potential treatment options available.

Formulary status definitions

Formulary (OK to be prescribed - but after any 1st or 2nd line options)

1st line formulary (when there are few formulary options, this is the 1st choice)

2nd line formulary (when there are few formulary options, this is the 2nd choice)

Where there is no preferred 1st line agent provided, the drug choice appears in alphabetical order.

1st line medicines for certain therapeutic groups and any restrictions placed upon prescribing are indicated in the box after the medicine name. Where modified release preparations of a formulary drug are available a comment will clarify its status. Newly licensed modified release preparations of existing formulary drugs will remain non-formulary until a review is carried out and recommendations are published. Where published guidance from NICE, MTRAC or the CSM is available, a reference to this is made either in the box after the medicine name or under the section title. Prescribing guidance issued by the Area Prescribing Committee is also included where it is available.



GMMMG Red/Amber/Green classifications



RED

Drugs considered to be specialist medicines and prescribing responsibility for these medicines should normally remain with the consultant or specialist clinician. These drugs should not be initiated or prescribed in primary care. It is recommended that the supply of these specialist medicines should be organised via the hospital pharmacy or specialist service. This may include arranging for supply via a home care company.

AMBER

Drugs suitable for shared care arrangements under a shared care protocol.

Prescribing and monitoring responsibilities may be transferred from specialist teams to primary care prescribers in line with a shared care protocol. Shared care arrangements will usually be supported by a GMMMG shared care protocol (SCP).

See here for a list of GMMMG approved SCPs.

GREEN

Drugs that are suitable for initiation and ongoing prescribing within primary care.

SA

Green following specialist advice. Drugs that are suitable for initiation by primary care following written or verbal advice from a specialist service. Little or no monitoring is required.

SI

Green following specialist initiation. Drugs that are suitable for ongoing prescribing within primary care following initiation by a specialist service. Little or no monitoring is required.

(DNP)

Products which are not recommended for prescribing in any setting. "Do Not Prescribe" status may relate to a specific medicine, or to prescribing for a particular indication. This is in addition to all medicines with a "not NHS" or "Drugs of Low Clinical Value" classification in the BNF, and those medicines with a NICE "Do not do" recommendation.

Criteria for inclusion on DNP/grey lists:

Criterion 1: Products of low clinical effectiveness, where there is a lack of robust evidence of clinical effectiveness or there are significant safety concerns.

Criterion 2: Products which are clinically effective but where more cost-effective products are available, including products that have been subject to excessive price inflation.

Criterion 3: Products which are clinically effective but, due to the nature of the product or condition being treated, are deemed a low priority for NHS funding.

GREY

Products which are not suitable for routine prescribing but suitable for exceptional use in a defined patient population. Prescribers should ensure that more suitable alternatives have been considered and ruled out as not being appropriate before recommending or prescribing a medicine with a GREY list status. In these cases a RAG of RED, AMBER or GREEN will also be assigned to clarify in which care setting prescribing responsibility lies.

Criteria for inclusion on DNP/grey lists:

Criterion 1: Products of low clinical effectiveness, where there is a lack of robust evidence of clinical effectiveness or there are significant safety

Criterion 2: Products which are clinically effective but where more cost-effective products are available, including products that have been subject to excessive price inflation.

Criterion 3: Products which are clinically effective but, due to the nature of the product or condition being treated, are deemed a low priority for NHS funding.

отс

In line with NHS England guidance, GM do not routinely support prescribing for conditions which are self-limiting or amenable to self-care.



Unlicensed indications are automatically classified as red unless designated otherwise on the list below. If a medicine is unlicensed this should be annotated as follows: drug name

Formulary symbols

MMC	Medicines Management Committee decisions
emc⊕	Electronic medicines compendium (SmPC & PIL)
BNF	British National Formulary (BNF)
BNF for children	British National Formulary for Children (BNFC)
NICE	NICE guidance
PbR X	NHS Payment Scheme (NHSPS) excluded medicine (previously known as PbR excluded)
<u>CD</u>	Controlled Drug
0	Unlicensed medicine
££	High cost medicine
blueteq	Blueteq enabled forms
MedTeq	MedTeq Enabled Forms
NOT STOCKED	Not routinely stocked, can be ordered if existing patient supply is exhausted

PCT Guidelines

Greater Manchester Medicines Management Group FORMULARY

GMMMG

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List

GMMMG Approved Shared Care Protocols

Useful Links

All Wales Medicines Strategy Group

British HIV Association (BHIVA)

British National Formulary (No password required)

British National Formulary for Children (No password required)

Commission on Human Medicines (CHM)

electronic Medicines Compendium (eMC)

General Pharmaceutical Council (GPhC)

Greater Manchester Medicines Management Group (GMMMG)

Medicines and Healthcare products Regulatory Agency (MHRA)

Midlands Therapeutics Review and Advisory Committee (MTRAC)

National Institute for Health and Clinical Excellence (NICE)

Scottish Medicines Consortium (SMC)

Specialist Pharmacist Service (SPS)

Section 1: Gastro-Intestinal system

Supported by the formulary (click here)



1.1 Dyspepsia & gastro-oesophageal reflux disease

- 1.1.1 Antacids & Simeticone
- 1.1.2 Compound Alginates & Proprietary Indigestion Preparations

1.2 Anti-spasmodics & other drugs altering gut motility

Antimuscarinics Other Antispasmodics Motility Stimulants

1.3 Antisecretory drugs & mucosal protectants

- 1.3.1 H₂-Receptor Antagonists
- 1.3.3 Chelates & Complexes
- 1.3.5 Proton Pump Inhibitors

1.4 Acute diarrhoea

1.4.2 Antimotility Drugs

1.5 Chronic bowel disorders

- 1.5.1 Aminosalicylates
- 1.5.2 Corticosteroids & Enemas
- 1.5.3 Drugs Affecting the Immune Response

Advanced therapies (biologic and targeted synthetic treatments)

1.6 Laxatives

- 1.6.1 Bulk-forming Laxatives
- 1.6.2 Stimulant Laxatives
- 1.6.3 Faecal Softeners
- 1.6.4 Osmotic Laxatives
- 1.6.5 Bowel Cleansing Preparation
- 1.6.6 Peripheral opioid-receptor antagonists
- 1.6.7 Other drugs used in constipation

1.7 Local preparations for anal & rectal disorders

- 1.7.2 Compound Haemorrhoidal Preparations with Corticosteroids
- 1.7.4 Management of anal fissures

1.9 Drugs affecting intestinal secretions

- 1.9.1 Drugs affecting biliary composition & flow
- 1.9.2 Bile acid sequestrants
- 1.9.4 Pancreatin

1.10 Miscellaneous preparations

Non-Formulary Items

Trust Guidelines

GASTRO / ENDOSCOPY - medicine & prescribing policies / guidelines (MFT Policy Hub)

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Biosimilar Medicines (KTT15)

Faecal Incontinence (CG49)

Irritable Bowel Syndrome (CG61)

Diarrhoea and vomiting in children under 5 (CG84)

Constipation in children and young people (CG99)

Acute upper GI bleeding (CG141)

Dyspepsia and gastro-oesophageal reflux disease (CG184)

Coeliac disease: recognition, assessment and management (NG20)

Crohn's disease: management (NG129)
Ulcerative colitis: management (NG130)

Ulcerative colitis (acute exacerbations) - infliximab (TA163)

Crohn's disease - infliximab & adalimumab (TA187)

Constipation (women) - prucalopride (TA211)

Infliximab, adalimumab & golimumab for treating moderately to severely active ulcerative colitis (TA329)

Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)

Naloxegol for treating opioid induced constipation (TA345)

Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)

Obeticholic acid for treating primary biliary cholangitis (TA443)

Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)

Tofacitinib for moderately to severely active ulcerative colitis (TA547)

Darvadstrocel for treating complex perianal fistulas in Crohn's disease (TA556)

Ustekinumab for treating moderately to severely active ulcerative colitis (TA633)

Naldemedine for treating opioid-induced constipation (TA651)

Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)

Filgotinib for treating moderately to severely active ulcerative colitis (TA792)

Teduglutide for treating short bowel syndrome (TA804)

Ozanimod for treating moderately to severely active ulcerative colitis (TA828)

Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)

Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)

Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905)

Mirikizumab for treating moderately to severely active ulcerative colitis (TA925)

Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over (TA956)

Risankizumab for treating moderately to severely active ulcerative colitis (TA998)

Elafibranor for previously treated primary biliary cholangitis (TA1016)


GMMMG Formulary


Formulary Homepage


Chapter 1: Gastro-Intestinal system


GMMMG Adult Red/Amber/Green; DNP and Grey Drug List


GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List











PbR X

infusion

enema


ICAM-1 Inhibitor Alicaforsen U

blueteq


MMC BNF emc


RESTRICTED Gastro. Consultants only - pouchitis

PBRX NICE MMC BNF emco











			·
Non-Formulary Items			Gм <mark>₩</mark> мG
Darvadstrocel (DNP)			REJECTED in line with NICE TA556
Alofisel® 5 million cells/mL injection	NICE MMC	<u>emc</u> ⊕	Criterion 1
Diarrhoea (adults) (DNP)			in line with GMMMG / NHSE
Dicycloverine hydrochloride (DNP)	BNI	=	in line with GMMMG
	BNF	emc⊚	Criterion 2
Haemorrhoids (DNP)			in line with GMMMG / NHSE
Indigestion and heartburn (DNP)			in line with GMMMG / NHSE
Infant colic (DNP)			in line with GMMMG / NHSE
Infrequent constipation (duration less than 2 weeks) (DNP)			in line with GMMMG / NHSE
IQoro (DNP)			in line with GMMMG
Neuromuscular training device			Criterion 1
Lactase drops (DNP)			in line with GMMMG
e.g Colief®			Criterion 1
Lubiprostone			Discontinued Jan-19
capsules	NICE MMC	emc⊚	
Macrogols Klean-Prep® oral powder	MMC BNF	emco	Discontinued Apr-24
OTC haemorrhoid preparations (DNP)			in line with GMMMG
Passandatrii	NICE BNI	≥ emc⊚	
Racecadotril (DNP)			in line with GMMMG
capsules; granules for oral suspension; tablets		emc⊚	Criterion 1
Rifaximin (DNP)	BNI		in line with GMMMG for Traveller's diarrhoea
200mg tablets (see also section 5.1.7)	NICE MMC BN	emc _®	
Stoma deodorant sprays (DNP)			in line with GMMMG
			Criterion 3
VSL#3® / Vivomixx® food supplement (DNP)			in line with GMMMG
			Criterion 1

Section 2: Cardiovascular system

Supported by the formulary (click here)



2.1 Positive inotropic drugs

- 2.1.1 Cardiac Glycosides
- 2.1.2 Phosphodiesterase Inhibitors

2.2 Diuretics

- 2.2.1 Thiazides & Related Diuretics
- 2.2.2 Loop Diuretics
- 2.2.3 Potassium-sparing Diuretics & Aldosterone Antagonists
- 2.2.4 Potassium-sparing Diuretics with other Diuretics
- 2.2.5 Osmotic Diuretics

2.3 Anti-arrhythmic drugs

2.3.2 Drugs for Arrhythmias

2.4 Beta-adrenoceptor blocking drugs

2.5 Hypertension & heart failure

- 2.5.1 Vasodilator Antihypertensive Drugs
- 2.5.2 Centrally Acting Antihypertensive Drugs
- 2.5.4 Alpha-Adrenoceptor Blocking Drugs
- 2.5.5 Drugs Affecting the Renin-Angiotensin System
 - 2.5.5.1 Angiotensin-Converting Enzyme (ACE) Inhibitors
 - 2.5.5.2 Angiotensin-II Receptor Antagonists
 - 2.5.5.3 Renin Inhibitors
 - 2.5.5.4 Heart Failure

2.6 Nitrates, calcium-channel blockers & other antianginals

- 2.6.1 Nitrates
- 2.6.2 Calcium-channel Blockers
- 2.6.3 Other Antianginal Drugs
- 2.6.4 Peripheral Vasodilators & Related Drugs

2.7 Sympathomimetics

- 2.7.1 Inotropic Sympathomimetics
- 2.7.2 Vasoconstrictor Sympathomimetics
- 2.7.3 Cardiopulmonary Resuscitation

2.8 Anticoagulants & protamine

- 2.8.1 Parenteral Anticoagulants
- 2.8.2 Oral Anticoagulants
- 2.8.3 Protamine Sulfate

2.9 Antiplatelet drugs

2.10 Stable angina, acute coronary syndromes & fibrinolysis

2.10.2 Fibrinolytic Drugs

- 2.11 Antifibrinolytic drugs & haemostatics
- 2.12 Lipid-regulating drugs
- 2.13 Local sclerosants
- 2.14 Miscellaneous preparations

Non-Formulary Items

Trust Guidelines

CARDIOLOGY - medicine & prescribing policies / guidelines (MFT Policy Hub)

CARDIAC SURGERY - medicine & prescribing policies / guidelines (MFT Policy Hub)

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Prophylaxis against infective endocarditis (CG64)

Familial hypercholesterolaemia (CG71)

Chest pain of recent onset (CG95)

Stable angina (CG126)

Lipid modification: CV risk assessment and the modification of blood lipids for the 1ry & 2ry prevention of CVD (CG181)

Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89)

Chronic heart failure in adults: diagnosis and management (NG106)

Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)

Hypertension in pregnancy: diagnosis and management (NG133)

Hypertension in adults: diagnosis and management (NG136)

Acute coronary syndromes (NG185)

Atrial fibrillation: diagnosis and management (NG196)

Volanesorsen for treating familial chylomicronaemia syndrome (HST13)

Acute coronary syndromes - glycoprotein Ilb/Illa inhibitors (review) (TA47)

Myocardial infarction - thrombolysis (TA52)

Guidance on the use of coronary artery stents (TA71) (partially updated by TA152)

Myocardial perfusion scintigraphy for the diagnosis and management of angina & MI (TA73) (partially updated bt TA95 & TA126)

Hypercholesterolaemia - Ezetimibe (TA132)

Coronary artery disease - drug eleuting stents (TA152)

Venous thromboembolism - dabigatran (TA157)

Rivaroxaban for the prevention of VTE (TA170)

Atrial Fibrillation - dronedarone (TA197)

Vascular disease - clopidogrel and dipyridamole (TA210)

Peripheral arterial disease - cilostazol, naftidrofuryl oxalate, pentoxifylline & inositol nicotinate (TA223)

Acute coronary syndromes - ticagrelor (TA236)

Venous thromboembolism - apixaban (hip and knee surgery) (TA245)

Atrial fibrillation - dabigatran etexilate (TA249)

Atrial fibrillation (stroke prevention) - rivaroxaban (TA256)

Venous thromboembolism (treatment & long term 2ry prevention) - rivaroxaban (TA261)

Stroke (acute, ischaemic) - alteplase (TA264)

Chronic heart failure - ivabradine (TA267)

Stroke & systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban (TA275)

Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban (TA287)

Prasugrel with PCI for treating ACS (review of TA182) (TA317)

Dabigatran etexilate for the treatment and 2ry prevention of DVT and/or PE (TA327)

Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)

Apixaban for the treatment and 2ry prevention of DVT and/or PE (TA341)

Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)

Edoxaban for preventing stroke and systemic embolism in people with non valvular atrial fibrillation (TA355)

Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)

Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)

Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)

Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)

Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)

Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)

Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)

Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA694)

Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)

Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)

Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)

Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)

lcosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)

Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)

Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA902)

Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (TA913)

Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA929)

Tenecteplase for treating acute ischaemic stroke (TA990)

Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over (TA1002)

Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over (TA1051)


GMMMG Formulary


Formulary Homepage


Chapter 2: Cardiovascular system

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List


GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List








	GM <mark>™</mark> MG
	NICE NG106
	NICE NG136
	NICE NG196
RNE PMC	
Sin Sincs	RESTRICTED adults. Cardiology Consultant only
MMC BNF emc	3
2000 E	RESTRICTED adults. Cardiology Consultant only
MMC BNF emc	ALSO 2ND LINE FOR VARICEAL BLEED
	RESTRICTED
	I.V. only
BNF emc	
	RESTRICTED Haematology Consultants - SCD
MMC	
	RESTRICTED
FINE CONTRACTOR	oral preps in pregnancy
BNF emc	
EUNTE	
BNF emco	
	RESTRICTED paeds. ventricular
88880	arrhythmias in long QT syndrome
MMC BNF emco	
BNF emco	
	RESTRICTED
SUNJE Reconstitute on	not in Cardiology
MMC BNF emc	
BNF emco	
	MMC BNF emc



2mg; 4mg & 8mg tablets


MMC BNF emc

2.5.5.2 Angiotensin-II Receptor Antagonists MHRA Drug Safety Update (Feb-16): Spironolactone and renin-angiotensin sy	stem drugs in heart failure: risk of potentially fatal hype	rkalaemia
Candesartan cilexetil GREEN 2mg; 4mg; 8mg; 16mg & 32mg tablets	MMC BNF @mc	1 st line use hypertension
Losartan potassium GREEN 12.5mg; 25mg; 50mg & 100mg tablets	BNF (emc	2 nd line use hypertension
Irbesartan GREEN		2 nd line use hypertension
75mg;150mg & 300mg tablets Valsartan GREEN	MMC BNF emc	2 nd line use hypertension
40mg;80mg & 160mg capsules Sacubitril / Valsartan SI	MMC BNF emc	RESTRICTED use in line with NICE TA388
24mg / 26mg; 49mg / 51mg & 97mg / 103mg tablets 2.5.5.3 Renin inhibitors	NICE MMC BNF emc	
Aliskiren (DNP)		RESTRICTED adults. Specialist initiation only
150mg; 300mg tablets	MMC BNF emc	
MHRA Drug Safety Update (Mar-12): Aliskiren (Rasilez ▼): risk of cardiovascu 2.5.5.4 Heart Failure	llar and renal adverse reactions	
Dapagliflozin SA Forxiga ® tablets	NICE MMC BNF (EMC	RESTRICTED adults. Specialist initiation in line with TA679
Empagliflozin SA	mme snr eme	RESTRICTED adults. Specialist initiation in line with TA773
Jardiance ® tablets	NICE MMC BNF emc	




infusion

2.7 Sympathomimetics		GM <mark>₩</mark> MG
2.7.1 Inotropic Sympathomimetics		
Dobutamine		RESTRICTED 1.V.
	FIN.(3)	Specialist use only
nfusion	BNF emc	
Oopamine hydrochloride		RESTRICTED /. V.
	BAIF	Specialist use only
fusion	BNF emco	
Oopexamine		RESTRICTED I.V.
		Specialist use only
fusion	BNF emc	
soprenaline		RESTRICTED /.V.
		Specialist use only
njection	BNF emc	
2.7.2 Vasoconstrictor Sympathomimetics		
Adrenaline acid tartrate O		Specialist use endoscopic sinus
	BINIE	surgery
in 1000 (0.1%w/v) cutaneous solution)	MMC BNF emc	
phedrine hydrochloride		RESTRICTED /.V.
	EME	Specialist use only
njection	BNF emc	
Metaraminol [©]		
	IS/N/IP	
njection	BNF emc	
Midodrine		Specialist use Cardiology /
SI		Healthcare of the elderly
ablets	MMC BNF emco	
loradrenaline acid tartrate		RESTRICTED I.V.
	BNF	Specialist use only
nfusion	BNF emc	
Phenylephrine hydrochloride		RESTRICTED I.V.
		Specialist use only
njection	BNF emco	
2.7.3 Cardiopulmonary Resuscitation		
drenaline / Epinephrine		
GREEN	ENIA	
njection	BNF emc	





© Manchester University NHS Foundation Trust 2025






2.10 Stable angina, ACS & fibrinolysis		Gм <mark>₩</mark> мG
Stable angina (BNF treatment summary)		
Acute coronary syndromes (BNF treatment summary)		
Fibrinolytic Drugs (BNF treatment summary)		NICE CG126
2.10.2 Fibrinolytic Drugs		NICE NG128
Tenecteplase		
RED		
injection	NICE MMC BNF EMC	•
Streptokinase		
RED		
infusion	NICE BNF emo	•
Urokinase		
RED		
injection	BNF emo	
Alteplase		RESTRICTED
RED	(23)A((2)	RESTRICTED
injection; infusion	NICE MMC BNF emo	•






Lipid-regulating drugs		
Alirocumab RED		RESTRICTED adults. Lipid Clinic Consultants in line with TA393
Praluent® injection	PBRX NICE MMC BNF CMC	•
Bempedoic acid (see also <i>Nustendi</i> ®) GREEN		RESTRICTED adults. Consultants in line with TA694
Nilemdo ® tablets	PBRX NICE MMC BNF EMC	•
Bempedoic acid with ezetimibe (see also Nilemdo®) GREEN		RESTRICTED adults. Consultants in line with TA694
Nustendi ® tablets	PBRX NICE MMC BNF EMC	•
Evinacumab RED	blue	RESTRICTED adults. Consultants in line with TA1002
Repatha® injection	PHRX NICE MMC BNF (emo	
Evolocumab RED	blue	
Repatha® injection	PBRX NICE MMC BNF emo	TA394
Icosapent ethyl		RESTRICTED adults in line with NICE TA805
Vazkepa® capsules	PBRX NICE MMC BNF EMC	•
Inclisiran Green		RESTRICTED adults. Consultants in line with TA733
Legvio ® injection	PERX NICE MMC BNF (emo	for Primary Care Referral
Lomitapide RED EE	blue	RESTRICTED adults. Lipid Clinic Consultants in line with NHSE
Lojuxta® capsules	PBRX MMC BNF emo	······································
Volanesorsen		RESTRICTED adults. Lipid Clinic
RED EE	bluet	Open cultinate in time with HOT40
Waylivra® injection	PHRX NICE MMC BNF CMC	

2.13 Local sclerosants	GMMG
Local Scierosants	
Ethanolamine oleate	
RED	
injection	emc _®
Sodium tetradecyl sulfate	
RED	
injection	emc⊚





Section 3: Respiratory system

Supported by the formulary (click here)



3.1 Bronchodilators

- 3.1.1 Adrenoceptor Agonists
- 3.1.2 Antimuscarinic Bronchodilators
- 3.1.3 Theophylline
- 3.1.4 Compound Bronchodilator Preparations
- 3.1.5 Peak Flow Meters, Inhaler Devices & Nebulisers Inhaler Devices

Nebuliser Diluent

3.2 Corticosteroids

Compound preparations

3.3 Cromoglicate & related therapy & leukotriene receptor antagonists

- 3.3.1 Cromoglicate & Related Therapy
- 3.3.2 Leukotriene Receptor Antagonists
- 3.3.3 Phosphodiesterase type-4 inhibitors

3.4 Antihistamines, hyposensitisation & allergic emergencies

- 3.4.1 Antihistamines
- 3.4.2 Allergen Immunotherapy
- 3.4.3 Allergic Emergencies

3.5 Respiratory stimulants & pulmonary surfactants

- 3.5.1 Respiratory Stimulants
- 3.5.2 Pulmonary Surfactants
- 3.6 Oxygen (refer to oxygen guidelines)
- 3.7 Mucolytics
- 3.8 Aromatic inhalations
- 3.9 Cough preparations
 - 3.9.1 Cough Suppressants

Cough Suppressants (Palliative Care ONLY)

- 3.9.2 Demulcent & expectorant cough preparations
- 3.10 Systemic Nasal Decongestants
- 3.11 Antifibrotics

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Idiopathic pulmonary fibrosis (CG163)

Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115)

Asthma pathway (BTS, NICE, SIGN) (NG244)

Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245)

Venom anaphylaxis - immunotherapy pharmalgen (TA246)

Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (review of TA133, TA201) (TA278)

Omalizumab for previously treated chronic spontaneous urticaria (TA339)

Roflumilast for treating chronic obstructive pulmonary disease (replaces TA244) (TA461)

Reslizumab for treating severe eosinophilic asthma (TA479)

Pirfenidone for treating idiopathic pulmonary fibrosis (replaces TA282) (TA504)

Benralizumab for treating severe eosinophilic asthma (TA565)

Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)

Mepolizumab for treating severe eosinophilic asthma (replacing TA431) (TA671)

Berotralstat for preventing recurrent attacks of hereditary angioedema (TA738)

Dupilumab for treating severe asthma with type 2 inflammation (TA751)

Palforzia for treating peanut allergy in children and young people (TA769)

Tezepelumab for treating severe asthma (TA880)

lvacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis (TA988)


GMMMG Formulary

Formulary Homepage


Chapter 3: Respiratory system

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List


GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List




3.1.4 Compound Bronchodilator Preparations		GMMMG
Aclidinium bromide with formoterol fumarate dihydrate		3 rd line use
GREEN		COPD maintenance
Duaklir Genuair®	MMC BNF emc	
Glycopyrronium bromide with formoterol fumarate		3 rd line use
GREEN		COPD maintenance
Bevespi Aerosphere®	MMC BNF emc	
Glycopyrronium bromide with indacaterol maleate		3 rd line use
GREEN		COPD maintenance
Ultibro®	MMC BNF emc	
Ipratropium bromide with salbutamol		
Combinent®		
Tiotropium bromide monohydrate with olodaterol hydrochloride	BNF emc	3 rd line use
GREEN GREEN		COPD maintenance
Spiolto Respirat®	MMC BNF emco	OOI D maintenance
Umeclidinium bromide with vilanterol trifenatate	MIMC BRF CITCS	3 rd line use
GREEN		COPD maintenance
Anoro Ellipta®	MMC BNF emco	oor B maintenance
3.1.5 Peak Flow Meters, Inhaler Devices & Nebulisers	Willia Eliza	GMMMG GMMMG GMMMG
Inhaler Devices		GG
Volumatic® (spacer inhaler)		
GREEN		
Large volume device with mouthpiece	NICE BNF emc	
Aerochamber® Plus (spacer device)		
GREEN		
Standard device with mouthpiece; Standard device with adult face mask	NICE BNF	
Able Spacer® (spacer device)		
GREEN		
	NICE MMC BNF	
Nebuliser Diluent		
Sodium chloride		
GREEN	[BNN]F	
0.9% nebuliser diluent	BNF emc	



MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration




3.4 Antihistamines, hyposensitisation &	k allergic emergenci	i es G∞MMG
3.4.1 Antihistamines		
Non-sedating antihistamines		
Cetirizine hydrochloride GREEN OTC		
	BUNIE for shidder	
tablets; oral solution	BNF	<u> </u>
Loratadine GREEN OTC		
tablets; oral solution	ENTE OMO	
Desionatadine	BNF emc	RESTRICTED
	ENVIE	children 1-2 years old
tablets; oral solution	MMC BNF emc	
Fexofenadine hydrochloride	WIND SILE	
отс	E18(8)	
tablets	MMC BNF emc	9
Sedating antihistamines		
Chlorphenamine maleate		
GREEN OTC	BINTE for children	
tablets; oral solution; injection	MMC BNF emc	⊚
Cyprohepatadine hydrochloride		
4mg tablets	MMC BNF emc	
Cyprohepatadine hydrochloride		Approved for use between Sep-24 &
		Dec-24 during tablet shortage
2mg/5mL liquid Hydroxyzine hydrochloride	MMC BNF emc	9
GREEN	POINT I P	
tablets; oral solution	SINIT Gorandon	
MHRA Drug Safety Update (Apr-15): Hydroxyzine (Atarax, Ucerax): risk of QT interval	prolongation and Torsade de Pointes	9
Promethazine hydrochloride	g	
	ENTE	
tablets; oral solution	MMC BNF emc	9
Alimemazine tartrate		
(DNP)	BINTE for children	
tablets; oral solution	MMC BNF emc	©
3.4.2 Allergen Immunotherapy		
Acaravac Plus ® U		RESTRICTED
	2000	Immunology Consultants only
3,000 units/mL injection Acaroid®	MIMIC	DESTRICTED
Acarolo		RESTRICTED Immunology Consultants only
injection	MMC	minunciogy consumante only
Allergoid immunotherapy tablets U	INTERPORT OF THE PROPERTY OF T	RESTRICTED
	BW =	Immunology Consultants only
Lofarma Lais ®	MMC BNF emc	
Bee venom extract		RESTRICTED
RED	ENG	Immunology Consultants only
injection	NICE BNF EMC	0
Grass & Rye or tree pollen extract		RESTRICTED
GREY RED	Ex manufacturer	Immunology Consultants only
Pollinex®	MMC BNF emc	
Grass pollen extract		RESTRICTED
	BNT Storichiden	Immunology Consultants only
Grazax® oral lyophilisates	NICE MMC BNF EMC	
House dust mite extract		RESTRICTED
Apprizay 12 SO HDM and hyphilipates®	NICE MANAGE	Immunology Consultants only
Acarizax 12-SQ HDM oral lyophilisates® Peanut protein powder	NICE MMC BNF emc	RESTRICTED
GREY RED	IIEZNI III	Immunology Consultants only
Palforzia ® oral powder in capsules; sachet	NICE MMC BNF emc	
Wasp venom extract	WIND THE	RESTRICTED
RED		Immunology Consultants only
injection	NICE MMC BNF emc	
White birch (Betula verrucosa) tree pollen extract		RESTRICTED
RED	[B3]VI[H]	Immunology Consultants only
Itulazax 12-SQ Bet oral lyophilisates®	MMC BNF emc	3



MMC

300mg; 600mg tablets




3.6 Oxygen (refer to oxygen guidelines)










3.8 Aromatic inhalations	Gw <mark>w</mark> wG
Aromatic Inhalations	
Benzoin Tincture, Compound, BP	
Friars' Balsam liquid	emc⊚
Menthol and Eucalyptus Inhalation, BP 1980	
	ENT
inhalation vapour	BNF emc



3.10 Systemic nasal decongestants

Gм<mark>Ж</mark>мG

Systemic Nasal Decongestants


NO DRUGS ARE RECOMMENDED FROM THIS GROUP



NHSE: OTC prescribing reduction

MHRA Drug Safety Update (Feb-24): Pseudoephedrine: risk of posterior reversible encephalopathy syndrome (PRES) & reversible cerebral vasoconstriction syndrome (RCVS)





Chapter 4: Central nervous system

Supported by the formulary (click here



- 4.1 Hypnotics & anxiolytics
 - 4.1.1 Hypnotics
 - 4.1.2 Anxiolytics
 - 4.1.3 Barbiturates
 - 4.1.4 Other hypnotics and anxiolytics
- 4.2 Drugs used in psychoses & related disorders
 - 4.2.1 Antipsychotic Drugs
 - 4.2.2 Antipsychotic Depot Injections
 - 4.2.3 Drugs used for mania and hypomania
- 4.3 Antidepressant drugs
 - 4.3.1 Tricyclic & Related Antidepressant Drugs
 - 4.3.2 Monoamine-Oxidase Inhibitors (MAOIs)
 - 4.3.3 Selective Serotonin Re-uptake Inhibitors (SSRIs)
 - 4.3.4 Other Antidepressant Drugs
- 4.4 CNS stimulants & drugs used for ADHD
- 4.5 Drugs used in the treatment of obesity
- 4.6 Drugs used in nausea & vertigo
- 4.7 Analgesics
 - 4.7.1 Non-Opioid Analgesics
 - 4.7.2 Opioid Analgesics
 - 4.7.3 Neuropathic Pain
 - 4.7.4 Antimigraine Drugs
- 4.8 Antiepileptic drugs
 - 4.8.1 Control of the Epilepsies
 - 4.8.2 Drugs Used in Status Epilepticus
- 4.9 Drugs used in Parkinsonism & related disorders
 - 4.9.1 Dopaminergic Drugs Used in Parkinsonism
 - 4.9.2 Antimuscarinic Drugs Used in Parkinsonism
 - 4.9.3 Drugs Used in Essential Tremor, Chorea, Tics & Related Disorders
- 4.10 Drugs used in substance dependence
- 4.11 Drugs for dementia
- Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Obsessive compulsive disorder (OCD) & body dismorphic disorder (BDD) (CG31)

Management of Obesity (CG43) (replaces TA22, TA31 & TA46)

Drug misuse: opioid detoxification (CG52)

Depression with a chronic physical health problem (CG91)

Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)

Anxiety (CG113) (replaces CG22)

Neuropathic pain - pharmacological management (CG173)

Psychosis and schizophrenia in adults (CG178)

Bipolar disorder: the assessment and management in adults, children & young people in 1ry & 2ry care (CG185)

Narcolepsy with or without cataplexy in adults: pitolisant (ES8)

Eating Disorders: recognition and treatment (NG69)

Parkinsons's disease in adults (NG71)

Attention deficit hyperactivity disorder: diagnosis and management (NG87)

Stop smoking interventions and services (NG92)

Dementia: supporting people with dementia and their carers in health and social care (NG97)

Post-traumatic stress disorder (NG116)

Depression in children and young people: identification and management (NG134)

Epilepsies in children, young people and adults (NG217)
Depression in adults: treatment and management (NG222)

Motor Neurone Disease: Riluzole (TA20)

Guidance on the use of zaleplon, zolpidem & zopiclone for short-term management of insomnia (TA77)

Drug Misuse: Methadone & Buprenorphine (TA114)

Drug Misuse: Naltrexone (TA115) Smoking Cessation: Varenicline (TA123) Schizophrenia - aripiprazole (TA213)

Alzheimer's disease - donepezil, galantamine, rivastigmine & memantine (TA217) (replaces TA111)

Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)

Bipolar disorder (children) - aripiprazole (TA292)

Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)

Vortioxetine for treating major depressive episodes (TA367)

Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)

Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)

Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)

Galcanezumab for preventing migraine (TA659)

Cenobamate for treating focal onset seizures in epilepsy (TA753)

Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy (TA758)

Fremanezumab for preventing migraine (replacing TA631) (TA764)

Fenfluramine for treating seizures associated with Dravet syndrome (TA808)

Vutrisiran for treating hereditary transthyretin-related amyloidosis (TA868)

Eptinezumab for preventing migraine (TA871)

Difelikefalin for treating pruritus in people having haemodialysis (TA890)

Rimegepant for preventing migraine (TA906)

Rimegepant for treating migraine (TA919)

Daridorexant for treating long-term insomnia (TA922)

Foslevodopa-foscarbidopa for treating advanced Parkinson's with motor symptoms (TA934)

Atogepant for preventing migraine (TA973)

Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA984)

Eplontersen for treating hereditary transthyretin-related amyloidosis (TA1020)


Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over (TA1050)

GMMMG Formulary


Formulary Homepage

Chapter 4: Central nervous system

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List




4.1.3 Barbiturates NO DRUGS ARE RECOMMENDED FROM THIS GROUP 4.1.4 Other hypnotics and anxiolytics Daridorexant hydrochloride GREEN Quviviq ® tablets RESTRICTED in line with NICE TA922 NOT for initiation in 2^{ry} care




4.2.3 Drugs used for mania and hypomania	
Lithium carbonate	PRESCRIBE BY BRAND NAME
AMBER RED	BNE
tablets; M/R tablets	BNF emc
Lithium citrate	PRESCRIBE BY BRAND NAME
AMBER RED	I INCOMPLE DI DIMITE IMML
oral solution	BNF emc
Valproic acid	
SI	ENT.
Gastro-resistant tablets	BNF @MC®
MHRA Drug Safety Update (Apr-19): Valproate medicines and serious	narms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance
MHDA Drug Safaty Undata (May 10): Carbananama: concemitant una	with valarais asid not recommended

4.3 Antidepressant drugs		GMMG
		NICE CG31
		NICE CG91
I.3.1 Tricyclic & Related Antidepressant Drugs		NICE NG134
Fricyclic antidepressants		NICE NG222
Amitriptyline hydrochloride (standard release preparations only)		
GREEN	BNF	
ablets; oral solution (see also section 7.4.2)	BNF emc	
Clomipramine hydrochloride (standard release preparations only)		
GREEN		
apsules	BNF emc	
Doxepin hydrochloride		
rapsules	BNF emc	
mipramine hydrochloride		
	BINIA	
ablets	BNF emco	
_ofepramine		1 st line use
GREEN		1 ine use
ablets; oral suspension	BNF emco	
Nortriptyline		
GREEN		
ablets	BNF emco	
Trimipramine		
(DNP)		
ablets; capsules	BNF emc	
Tricyclic-related antidepressants		
Mianserin hydrochloride		RESTRICTED
		initiation by Psychiatrist
ablets	BNF emc	
Trazodone hydrochloride		RESTRICTED
GREEN		initiation by Psychiatrist
capsules; tablets; oral solution	BNF emc	
4.3.2 Monoamine-Oxidase Inhibitors (MAOIs)		
socarboxazid		RESTRICTED
RED		initiation by Psychiatrist
ablets	BNF emc	
Phenelzine		RESTRICTED
RED		initiation by Psychiatrist
5mg tablets	BNF emc	
Tranylcypromine		RESTRICTED
RED		initiation by Psychiatrist
Omg tablets	BNF emc	
Reversible Monoamine-Oxidase Inhibitors (MAOIs)		
Moclobemide		RESTRICTED 2 nd line
SI		initiation by Psychiatrist
150mg; 300mg tablets	BNF emc	
4.3.3 Selective Serotonin Re-uptake Inhibitors (SSRIs)		
MHRA Drug Safety Update (Jan-21): SSRI/SNRI antidepressant medicines: small increased risk of p	ostpartum haemorrhage when used i	in the month before delivery
Fluoxetine		·
GREEN	BNF	
capsules; tablets; dispersible tablets; oral solution	MMC BNF emc	
Citalopram	5	
GREEN		
ablets; oral drops	MMC BNF emc	
MHRA Drug Safety Update (Jul-16): Citalopram: suspected drug interaction with cocaine; prescribers		it drug use
/IHRA Drug Safety Update (Dec-11): Citalopram and escitalopram: QT interval prolongation		
Sertraline		
GREEN	BUNIF Nor shiftener	
ablets; oral suspension	MMC BNF emc	
	BINE for shallown	
Fluvoxamine maleate	BNF emc	
Fluvoxamine maleate	BNF (emco	
Fluvoxamine maleate	BNF (emcs)	

Escitalopram		RESTRICTED
		Mental Health Trust initiation only
ablets	BNF emco	
MHRA Drug Safety Update (Dec-11): Citalopram and escitalopram: QT in	nterval prolongation	
1.3.4 Other Antidepressant Drugs		
/enlafaxine		RESTRICTED
GREEN SI		initiation by Psychiatrist
1/R capsules; tablets; M/R tablets	MMC BNF emc	
f irtazapine	emc⊚	
GREEN		
ablets; orodisperible tablets; oral solution	MMC BNF emc	
Duloxetine		RESTRICTED
GREEN		initiation by Psychiatrist
jastro-resistant tablets	BNF emc	
Flupentixol		RESTRICTED
		initiation by Psychiatrist
ablets	BNF emc	
Reboxetine		RESTRICTED
		initiation by Psychiatrist
ablets	MMC BNF emco	
Fryptophan	initial of the second of the s	RESTRICTED
Never 1		initiation by Psychiatrist
apsules	BNF @MC®	
/ortioxetine	BNF CIICO	RESTRICTED
GREY SA		initiation by Psychiatrist
		initiation by Fayomathist
ablets	NICE MMC BNF EMCO	




4.5 Drugs used in the treatment of obesity 4.5.1 Anti-Obesity Drugs Acting on the Gastro-Intestinal Tract Orlistat GREEN Consultant initiation - Paeds. only MHRA Drug Safety Update (Mar-14): Orlistat: theoretical interaction with antiretroviral HIV medicines




tablets

BNF emc




<u>emc</u> Clonidine hydrochloride tablets BNF emc® Rimegepant (migraine prophylaxis) **RESTRICTED** Neurology initiation only in line GMMMGVydura® 75mg oral lyophilisate with NICE / GMMMG MMC BNF emc®





MMC

emc_®

Ospolot® 50mg tablets







4.11 Drugs for dementia		GMMG
4.11 Drugs for Dementia		NICE NG97
Donepezil hydrochloride SA		RESTRICTED Specialist use only
tablets; orodispersible tablets	NICE MMC BNF EMC	
Galantamine SA		RESTRICTED Specialist use only
M/R capsules	NICE BNF emc	
MHRA Drug Safety Update (Dec-15): Letters sent to healthcare professionals		
Memantine hydrochloride		RESTRICTED
SA		Specialist use only
tablets; oral solution	NICE MMC BNF emc	
Rivastigmine		RESTRICTED
GREEN		Specialist use only
capsules; oral solution; transdermal patches	NICE MMC BNF emc	

MFT Formulary v10.6 (June 2025)	Section 4			Central Nervous System
Non-Formulary Items				GM <mark>™</mark> MG
Aspirin and codeine				in line with GMMMG
Co-codaprin® tablets; dispersible tablets		PNE	(ama)	Criterion 2
Cannabis-derived, cannabis-based and hemp products		BNF	emc	
(DNP)				in line with GMMMG
with the exception of nabilone and Epidyolex® Dextropropoxyphene with paracetamol				Criterion 1
(DNP)				in line with GMMMG
Co-proxamol®	NICE	BNF	emc⊚	
Dosulepin hydrochloride (DNP)				in line with GMMMG
tablets; capsules		BNF	emc _®	Criterion 1
Electromagnetic pulse therapy (DNP)				in line with GMMMG
ActiPatch®				Criterion 1
Eplontersen sodium				MFT not a commissioned centre
RED				patients referred to NAC - Royal Free
Wainzua ® 45mg/0.8mL injection Eptinezumab	MR	MC BNF	emc _®	
RED (1)				
injection	MI	MC BNF	emc _®	NOT STOCKED
Erenumab RED (12)				
injection	NICE MI	MC BNF	emc	NOT STOCKED
Ergotamine-containing products				in line with GMMMG
(DNP)				Criterion 1
e.g. Migril® Esketamine				
(DNP)				in line with GMMMG
Spravato ® nasal spray Fremanezumab	NICE MI	MC BNF	emc _®	Criterion 1
RED (E)			blueteq	
injection	NICE MI	MC BNF		NOT STOCKED
Galantamine				RESTRICTED Specialist use only
4mg; 8mg & 12mg tablets	NICE	BNF	emc _®	opecialist use only
Galcanezumab				
injection	9.00	MO CONE	(ama (a)	NOT STOCKED
Ganaxolone		MC BNF	emc	
				in line with NICE
Ztalmy ® 50mg/mL oral suspension Haloperidol	NICE MI	MC	<u>emc</u> ⊕	
(DNP)				in line with GMMMG
500microgram tablets	NICE MI	MC BNF	<u>emc</u> ⊚	Criterion 2
Infrequent migraine (DNP)				in line with GMMMG / NHSE
Levomepromazine (DNP)				in line with GMMMG
6mg tablets		BNF for children	Omc@	
Loxapine		DINF	CITIC®	in line with CMMAC
(DNP)				in line with GMMMG
inhalation powder Meprobamate		BNF		Criterion 1
(DNP)				in line with GMMMG
tablets				Criterion 1
Meprobamate (DNP)				in line with GMMMG
tablets				Criterion 1
Mild toothache / teething (DNP)				in line with GMMMG / NHSE
e.g. paracetamol, ibuprofen, teething gels.				
e.g. parasolumor, isaproton, toluming gots.				

Minor conditions associated with pain, discomfort and/or fever (DNP)			in line with GMMMG / NHSE
e.g. aches and sprains, headache, period pain, back pain			
Nicotine (DNP)			in line with GMMMG
e-Voke ®, Voke ® (Nicotine inhaler)			Criterion 1
Omaveloxolone			Not recommended by NICE
Skyclarys® 50mg hard capsules	NICE MMC	emc⊚	
Oxycodone with naloxone			in line with GMMMG
	2424	(Criterion 2
Farginact® M/R tablets Paracetamol and tramadol	MMC BNF	<u>emc⊕</u>	Criterion 2
(DNP)		.	in line with GMMMG
ablets; effervescent tablets	BNF	emc	Criterion 2
Paracetamol mixture / mucilage			in line with GMMMG
	ent		Criterion 1
Paracetamol with buclizine and codeine			in line with GMMMG
			Criterion 1
Aigraleve ® (all presentations) Paracetamol with isometheptene			Officerion 1
(DNP)			in line with GMMMG
/lidrid® 325mg / 65mg caspules			Criterion 1
Gufentanil citrate (DNP)	BINI		in line with GMMMG
alviso® 30microgram sublingual tablets	BNF	emc⊚	Criterion 2
Tafamidis RED			MFT not a commissioned centre patients referred to NAC - Royal Free
/yndaqel® capsules	NICE MMC BNF	emc _®	
Travel sickness (DNP)			in line with GMMMG / NHSE
/utrisiran			MFT not a commissioned centre
RED			patients referred to NAC - Royal Free
Amvuttra® injection	NICE MMC BNF	emc⊕	

Section 5: Infections

Supported by the formulary (click here)



5.1 Antibacterial drugs

- 5.1.1 Penicillins
- 5.1.2 Cephalosporins, Carbapenems & other Beta-Lactams
- 5.1.3 Tetracyclines
- 5.1.4 Aminoglycosides
- 5.1.5 Macrolides
- 5.1.6 Clindamycin
- 5.1.7 Some other Antibacterials
- 5.1.8 Sulfonamides & Trimethoprim
- 5.1.9 Antituberculosis Drugs
- 5.1.10 Antitleprotic Drugs
- 5.1.11 Metronidazole & Tinidazole
- 5.1.12 Quinolones
- 5.1.13 Urinary-tract Infections

5.2 Antifungal drugs

- 5.2.1 Triazole Antifungals
- 5.2.3 Polyene Antifungals
- 5.2.4 Echinocandin Antifungals
- 5.2.5 Other Antifungals

5.3 Antiviral drugs

- 5.3.1 HIV Infection
- 5.3.2 Herpesvirus Infection
- 5.3.3 Viral Hepatitis
- 5.3.4 Influenza
- 5.3.5 Respiratory Syncytial Virus (RSV)

5.4 Antiprotozoal drugs

- 5.4.1 Antimalarials
- 5.4.2 Amoebicides
- 5.4.3 Trichomonacides
- 5.4.4 Antigiardial drugs
- 5.4.5 Laistana aisa sista
- 5.4.5 Leishmaniacides 5.4.7 Drugs for toxoplasmosis
- 5.4.8 Drugs for pneumocystis pneumonia

5.5 Anthelmintics

- 5.5.1 Drugs for Threadworms (pinworms, Enterobius vermicularis)
- 5.5.2 Ascaricides
- 5.5.5 Schistosomicides (bilharziasis)
- 5.5.6 Filaricides

Non-Formulary Items

Trust Guidelines

MFT Adult Antimicrobial guidelines

MFT Paediatric Antimicrobial guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Prophylaxis against infective endocarditis (CG64)

Bacterial meningitis and meningococcal septicaemia (CG102)

Infection: Prevention & control of healthcare-associated infections in primary & community care (CG139)

Hepatitis B (Chronic) (CG165)

Tuberculosis (NG33)

Sinusitis (acute): antimicrobial prescribing (NG79) Sore throat (acute): antimicrobial prescribing (NG84) Otitis media (acute): antimicrobial prescribing (NG91)

Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing (NG117)

Cough (acute): antimicrobial prescribing (NG120)

Surgical site infections: prevention and treatment (NG125)

Hepatitis C: Chronic (TA75) (extended by TA106 - partially updated by TA200 & TA300)

Hepatitis B: Chronic (TA96) (partially updated by CG165)

Hepatitis C: Peginterferon & Ribavirin (TA106) (partially updated by TA200 & TA300)

Hepatitis B: Entecavir (TA153) Hepatitis B: Telbivudine (TA154)

Oseltamivir, Amantadine & Zanamivir for prophylaxis of Influenza (TA158)

Oseltamivir, Amantadine & Zanamivir for treatment of Influenza (TA168)

Hepatitis B: Tenofovir disoproxil (TA173)

Hepatitis C - peginterferon alfa and ribavirin (TA200) (read in conjunction with TA75 & TA106)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276)

Hepatitis C (children and young people) - peginterferon alfa & ribavirin (TA300)

Sofosbuvir for treating chronic hepatitis C (TA330)

Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)

Ledipasvir-sofosbuvir for treating chronic hepatitis C (TA363)

Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)

Elbasvir-grazoprevir for treating chronic hepatitis C (TA413)

Sofosbuvir-velpatasvir for treating chronic hepatitis C (TA430)

Glecaprevir-pibrentasvir for treating chronic hepatitis C (TA499)

Sofosbuvir-velpatasvir-voxilaprevir for treating chronic hepatitis C (TA507)

Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)

Cabotegravir with rilpivirine for treating HIV-1 (TA757)

Maribavir for treating refractory cytomegalovirus infection after transplant (TA860)

Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)

Bulevirtide for treating chronic hepatitis D (TA896)

Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)

Molnupiravir for treating COVID-19 (TA1056)

GMMMG Formulary

Formulary Homepage

Chapter 5: Infections

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List

RESTRICTED USE ANTIBIOTICS

- 1. Must be recommended / approved for use by consultant medical microbiologist
- 2. The name of the microbiologist must be documented on the prescription chart. The indication must be documented.
- 3. Only available from Pharmacy

RESERVED USE ANTIBIOTICS

5.1.2.1 Cephalosporins

1. Can be used only in accordance with the restrictions outlined below. 2. Indication must be clearly documented on the prescription chart. 3. If being used outside of guidelines Microbiology approval must be sought as above **UNRESTRICTED USE ANTIBIOTICS** 1. Can be used according to MFT Trust guidelines, (those drugs not marked Restricted or Reserved) 5.1 Antibacterial drugs GMMMG GMMMG 5.1.1 Penicillins 5.1.1.1 Benzylpenicillin & Phenoxymethylpenicillin Benzylpenicillin sodium (Penicillin G) 600mg injection BNF emc Phenoxymethylpenicillin (Penicillin V) BNF emc Benzathine benzylpenicillin (1) **RESTRICTED** unlicensed treatment for syphilis BNF emc 5.1.1.2 Penicillinase-Resistant Penicillins **Flucloxacillin** capsules; injection; oral solution MMC BNF emc **Temocillin RESTRICTED** infection caused by multi-resistant coliforms. **Micro only** MMC BNF emc 5.1.1.3 Broad Spectrum Penicillins **Amoxicillin** capsules; oral suspension; injection BNF emc Co-amoxiclav


	LEX.R.V.L.P* for children	
tablets; oral suspension; injection	BNF emc	
5.1.1.4 Antipseudomonal Penicillins		
Piperacillin with tazobactam		RESERVED
	ESIN III	serious / resistant infections
injection	MMC BNF emc	
Ticarcillin with clavulanic acid		RESERVED
	EST NI (F) GE CHARLES	serious / resistant infections
Timentin® 3.2g injection	MMC BNF emc	
5.1.1.5 Mecillinams		
Pivmecillinam hydrochloride		RESTRICTED UTIs caused by
	BINIF for children	resistant coliforms
	0.00.00	


	For children	resistant coliforms
200mg tablets	MMC BNF emc	
5.1.2 Cephalosporins, Carbapenems & other Beta-Lactams		BNF BNF BNF

•		
Cefalexin		
	ESLATION FOR CONTRACTOR OF CON	
caspules; tablets; oral suspension	BNF emc	
Cefazolin		DESTRICTED
	FILMER	RESTRICTED
injection	MMC BNF emc	on Micro. advice only
Cefotaxime		RESERVED
	BALL	as per guidelines for children
injection	BNF emco	
Ceftriaxone		RESERVED
	高級	as per guidelines for children
injection	PNE OMCO	

injection	MMC BNF emc	on Micro. advice only
Cefotaxime		RESERVED
	ENTE Company	as per guidelines for children
injection	BNF emc	
Ceftriaxone		RESERVED
	THE STATE OF THE S	as per guidelines for children
injection	BNF emc	
Cefuroxime		RESERVED
	ES N III.	as per guidelines for children
injection	BNF emc	

Cefixime tablets		
tablets		RESERVED
tablets	ENTE for children	GU infections only
	MMC BNF emc	<u> </u>
Ceftazidime		RESERVED
		pseudomonas infection in CF
injection	MMC BNF emc	(A)
Cetazidime with avibactam	101101 6 11110	RESERVED for
		gram negative organisms
7	11110	
Zavicefta ® infusion Ceftolozane sulfate with tazobactam sodium	MMC BNF emc	
Certolozarie Suriate with tazobactam Sodium		RESERVED for
		gram negative organisms
Zerbaxa® infusion	MMC BNF emc	Micro. Consultant only
Ceftaroline fosamil		RESERVED
	SMF	CAP & cSSTI treatment.
Zinforo® infusion	MMC BNF emc	Micro. Consultant only
Cefoxitin		RESERVED for treatment of
		mycobacterium abscessus in CF.
injection	MMC BNF emc	Micro. Consultant only
Cefiderocol		RESERVED for
		gram negative organisms
Fetcroja® infusion	MMO CONCE	
·	MMC BNF emc	
5.1.2.2 Carbapenems		
Ertapenem		RESTRICTED
	for children	Outpatient therapy only
infusion	MMC BNF emc	0
Imipenem with cilastatin		RESTRICTED
		Non-Tuberculous Mycobacteria in CF
infusion	MMC BNF emc	
Imipenem with cilastatin & relebactam	INITIAL CITIC	9
EE		RESTRICTED
		Micro Consultant only
Recarbrio ® infusion	MMC BNF emc	
Meropenem		RESERVED
	ENTE for children	as per guidelines
injection	MMC BNF emc	0
Meropenem with vaboractam		550501055
		RESTRICTED
Vaborem® infusion	MMC BNF emc	Micro. Consultant only
5.1.2.3 Other Beta-Lactam antibiotics	WING CITIC	9
Aztreonam		RESTRICTED
rea contain	and NO Office	gram negative organisms
	for children	
injection	BNF emc	
Aztreonam lysine		RESTRICTED 3 rd line CF patients with
RED ££	ENT F	chronic pulmonary infection
Cayston® nebuliser solution	MMC BNF emc	0
Aztreonam with avibactam sodium		
	BINIE	
Emblayeo® infusion	MMC BNF emc	
5.1.3 Tetracyclines	IVIIVIO CITIC	9
Doxycycline		
	ESINIE for children	
capsules; tablets; dispersible tablets	MMC BNF emc	9
Oxytetracycline		
A-bi-a-	BNF emc	(a)
tablets		RESTRICTED
Demeclocycline hydrochloride		
		SIADH only
Demeclocycline hydrochloride	MMC CONE	SIADH only
Demeclocycline hydrochloride capsules (see also section 6.5.2)	MMC BNF emc	⊚
Demeclocycline hydrochloride	MMC BNF emc	● RESTRICTED
Demeclocycline hydrochloride capsules (see also section 6.5.2) Lymecycline	EST N 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	RESTRICTED Non-Formulary
Demeclocycline hydrochloride capsules (see also section 6.5.2) Lymecycline 408mg capsules (see also section 13.6.2)	MMC BNF emc	RESTRICTED Non-Formulary
Demeclocycline hydrochloride capsules (see also section 6.5.2) Lymecycline	EST N 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	RESTRICTED Non-Formulary
Demeclocycline hydrochloride capsules (see also section 6.5.2) Lymecycline 408mg capsules (see also section 13.6.2)	EST N 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	RESTRICTED Non-Formulary
Demeclocycline hydrochloride capsules (see also section 6.5.2) Lymecycline 408mg capsules (see also section 13.6.2)	MMC BNF emc	RESTRICTED Non-Formulary MMC approved for GP referral
Demeclocycline hydrochloride capsules (see also section 6.5.2) Lymecycline 408mg capsules (see also section 13.6.2) Minocycline capsules; tablets	EST N 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	RESTRICTED Non-Formulary MMC approved for GP referral
Demeclocycline hydrochloride capsules (see also section 6.5.2) Lymecycline 408mg capsules (see also section 13.6.2) Minocycline	MMC BNF emc	RESTRICTED Non-Formulary MMC approved for GP referral RESERVED
Demeclocycline hydrochloride capsules (see also section 6.5.2) Lymecycline 408mg capsules (see also section 13.6.2) Minocycline capsules; tablets	MMC BNF emc	RESTRICTED Non-Formulary MMC approved for GP referral RESERVED as per guidelines





tablets (see also section 11.3.1) BNF emc MHRA Drug Safety Update (Jan-24): Fluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects

MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk

MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection


tablets


Ofloxacin


MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions / precautions for use due to reports of disabling & potentially long-lasting or irreversible side effects MHRA Drug Safety Update (Nov-18): Systemic & inhaled fluoroquinolones: small increased risk of aortic aneurysm & dissection; advice for prescribing in high-risk patients


RESTRICTED GU infections only

BNF emc









PBRX NICE MMC BNF EMC®

Baraclude ® tablets

Dectova® 10mg/mL infusion

Synagis ® 100mg/mL injection

Palivizumab


RED EE

Ribavirin


RED ££

capsules: tablets

5.3.5 Respiratory Syncytial Virus (RSV)



5.4.5 Leishmaniacides	
Meglumine antimoniate 🔍	RESTRICTED
RED	treatment of Leishmaniacides
njection	MMC BNF emc
Paromomycin [©]	RESTRICTED
RED	treatment of Crypotosporidios
ablets	MMC BNF emc
Sodium stibogluconate	RESTRICTED
RED	treatment of Leishmaniacides
injection	MMC BNF emc
5.4.7 Drugs for toxoplasmosis	
Sulfadiazine [©]	RESTRICTED
RED	treatment of toxoplasmosis
tablets	BNF emc micro. recommendation only
5.4.8 Drugs for pneumocystis pneumonia	
Atovaquone	RESTRICTED
RED	Specialist use only
oral suspension	BNF emc
Pentamidine isethionate	RESTRICTED
RED	Specialist use only
injection	BNF emc



Section 6: Endocrine system

Supported by the formulary (click here)



6.1 Drugs used in diabetes

6.1.1 Insulins

- 6.1.1.1 Short-acting insulins
- 6.1.1.2 Intermediate & long-acting insulins

Biphasic insulins

6.1.2 Antidiabetic drugs

- 6.1.2.1 Sulphonylureas
- 6.1.2.2 Biguanides
- 6.1.2.3 Other antidiabetic drugs

Alpha alucosidase inhibitors

Dipeptidyl peptidase-4 (DPP-4) inhibitors

Rapid acting insulin secretagogues (meglitinides)

Glucagon-like peptide-1 (GLP-1) receptor agonists

Sodium-glucose co-transporter 2 (SGLT2) inhibitors

Thiazolidinediones

- 6.1.4 Treatment of hypoglycaemia
- 6.1.5 Treatment of diabetic nephropathy and neuropathy
- 6.1.6 Diagnostic and monitoring agents for diabetes mellitus

6.2 Thyroid & antithyroid drugs

- 6.2.1 Thyroid hormones
- 6.2.2 Antithyroid drugs
- 6.3 Corticosteroids
 - 6.3.1 Replacement therapy
 - 6.3.2 Glucocorticoid therapy

6.4 Sex hormones

- 6.4.1 Female sex hormones and their modulators
 - 6.4.1.1 Oestrogens & HRT
 - 6.4.1.2 Progestogens and progesterone receptor modulators
- 6.4.2 Male sex hormones & antagonists

6.5 Hypothalamic and pituitary hormones & anti-oestrogens

- 6.5.1 Hypothalamic & anterior pituitary hormones & anti-oestrogens
- 6.5.2 Posterior pituitary hormones & antagonists

6.6 Drugs affecting bone metabolism

- 6.6.1 Calcitonin & parathyroid hormone
- 6.6.2 Bisphosphonates & other drugs affecting bone metabolism

6.7 Other endocrine drugs

- 6.7.1 Bromocriptine & other dopaminergic drugs
- 6.7.2 Drugs affecting gonadotrophins
- 6.7.3 Metyrapone
- 6.7.4 Somatomedins

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Safer insulin prescribing (KTT20)

Diabetes in pregnancy: management from preconception to the postnatal period (NG3)

Type 1 diabetes in adults: diagnosis and management (NG17)

Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)

Diabetic foot problems: prevention and management (NG19)

Type 2 diabetes in adults: management (NG28)

Heavy menstrual bleeding: assessment and management (NG88)

Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)

Human growth hormone - adults (TA64)

Diabetes (type 1) - insulin pump therapy (TA151)

Osteoporosis - Primary Prevention (TA160)

Osteoporosis - Secondary Prevention (TA161)

Human growth hormone (somatropin) for the treatment of growth failure in children (review) (TA188)

Osteoporotic Fractures - denosumab (TA204)

Bone metastases from solid tumours - denosumab (TA265)

Type 2 diabetes - Dapagliflozin combination therapy (TA288)

Diabetes (type 2) - canagliflozin (TA315)

Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)

Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)

Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)

Bisphosphonates for treating osteoporosis (TA464)

Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)

Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)

Dapagliflozin with insulin for treating type 1 diabetes (TA597)

Sotagliflozin with insulin for treating type 1 diabetes (TA622)

ti distantial distanti

Liraglutide for managing overweight and obesity (TA664)

Dapagliflozin for treating chronic kidney disease (TA775) Romosozumab for treating severe osteoporosis (TA791)

Relugolix-estradiol-norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)

Somatrogon for treating growth disturbance in people 3 years and over (TA863)

Tirzepatide for treating type 2 diabetes (TA924)

Empagliflozin for treating chronic kidney disease (TA942)

Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)

Abaloparatide for treating osteoporosis after menopause (TA991)

Burosumab for treating X-linked hypophosphataemia in adults (TA993)

Linzagolix for treating moderate to severe symptoms of uterine fibroids (TA996)

Tirzepatide for managing overweight and obesity (TA1026)

Relugolix-estradiol-norethisterone for treating symptoms of endometriosis (TA1057)

Somapacitan for treating growth hormone deficiency in people 3 to 17 years (TA1066)

Linzagolix for treating symptoms of endometriosis (TA1067)


GMMMG Formulary

Formulary Homepage

Chapter 6: Endocrine system

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List



MHRA Drug Safety Update (Nov-23): Ozempic ▼ (semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products

MMC BNF emc

NICE MMC BNF emc

NICE MMC BNF emc

Ozempic ® injection

Semaglutide

Rybelsus® tablets

Mounjaro ® injection

Tirzepatide

GREEN


GREEN

RESTRICTED


as per by $\operatorname{\mathsf{GMMMG}}$


RESTRICTED

as per NICE / GMMMG T2DM pathway see also Non-formulary section



MHRA Drug Safety Update (Oct-24): Insulin pumps & CGM equipment: guidance for users on reporting suspected adverse incidents & safety concerns to the MHRA's Yellow Card







WIFT FORMulary V10.0 (June 2025)	011 0	Endocrine System
6.4 Sex hormones		Gм <mark>₩</mark> мG
.4.1 Female sex hormones and their modulators		
.4.1.1 Oestrogens & HRT		
Conjugated oestrogens with progestogen		
Premique® (Conjugated oestrogens with medroxyprogesterone)		2 nd line use oral
GKEEN		(continuous combined HRT)
blets	BNF emco	
stradiol with Progestogen		
ijuve® (Estradiol with progesterone)		
GREEN		
ma/400ma conculos	14140	
mg/100mg capsules	MMC BNF emc	. et
Elleste-Duet® (Estradiol with norethisterone)		1 st line use oral
		(sequential HRT)
blets	BNF emco	
vorel Conti® (Estradiol with norethisterone)		
GREEN		
atch	MMC BNF emco	
vorel Sequi® (Estradiol with norethisterone)	WING BRIF CITICS	
GREEN (Light add of With Horothisterone)		
atch	MMC BNF emc	
emoston® (Estradiol with dydrogesterone)		2 nd line use oral
GREEN		(sequential HRT)
blets	BNF emco	
Cliovance® (Estradiol with norethisterone)	BIN- CITICS	1 st line use oral
GREEN (LISTINGION WITH HOTELHISTOTIC)		
		(continuous combined HRT)
blets	MMC BNF emc	
stradiol only		
Illeste Solo®		1 st line use oral
GREEN		(oestrogen only HRT)
blets	BNF emc	` ,
istradot®	BNF CITICS	RESTRICTED
GREEN GREEN		(Oestrogen only HRT)
		when oral contraindicated.
		when or al contraindicated.
atch	BNF emc	
Evorel® GREEN		RESTRICTED
GREEN		Paed. Endocrine Consultants
atch	MMC BNF emc	
enzetto®		
GREEN		
anadarmal anray	MMC COVER COMO	
ansdermal spray	MMC BNF emc	
Destrogel® Green		
GREEN		
06% gel (pump-pack)	MMC BNF emc	
Progynova®		RESTRICTED 2 nd line
RED		Paed. Endocrine Consultants
ng tablets	MMC CONC.	
ng lablets Randrena®	MMC BNF emc	
andrena & Green		
Omicrogram; 1mg gel sachets	MMC BNF emc	
thinylestradiol, raloxifene & tibolone		
thinylestradiol U		RESTRICTED
thinylestradiol [©]	THE REAL PROPERTY OF THE PROPE	
	Expense Control of the Control of th	adults: amenorrhoea
microgram tablets	MMC BNF emc	adults: amenorrhoea paeds: pubertal induction (3 rd line
microgram tablets aloxifene hydrochloride	MMC BNF emc	adults: amenorrhoea paeds: pubertal induction (3 rd line RESTRICTED
microgram tablets	MMC BNF emc	adults: amenorrhoea paeds: pubertal induction (3 rd line
microgram tablets caloxifene hydrochloride SA	MMC BNF emc	adults: amenorrhoea paeds: pubertal induction (3 rd line RESTRICTED
microgram tablets caloxifene hydrochloride SA blets	_	adults: amenorrhoea paeds: pubertal induction (3 rd line RESTRICTED Specialist Med. Consultant only NICE TA160 / TA161
microgram tablets caloxifene hydrochloride SA blets ibolone	_	adults: amenorrhoea paeds: pubertal induction (3 rd line RESTRICTED Specialist Med. Consultant only NICE TA160 / TA161 3 rd line use oral
microgram tablets aloxifene hydrochloride SA blets ibolone GREEN	NICE MMC BNF emc	adults: amenorrhoea paeds: pubertal induction (3 rd line RESTRICTED Specialist Med. Consultant only NICE TA160 / TA161
microgram tablets aloxifene hydrochloride SA blets ibolone GREEN blets	_	adults: amenorrhoea paeds: pubertal induction (3 rd line RESTRICTED Specialist Med. Consultant only NICE TA160 / TA161 3 rd line use oral
microgram tablets aloxifene hydrochloride SA blets ibolone GREEN blets 4.1.2 Progestogens and progesterone receptor modulators	NICE MMC BNF emc	adults: amenorrhoea paeds: pubertal induction (3 rd line RESTRICTED Specialist Med. Consultant only NICE TA160 / TA161 3 rd line use oral
microgram tablets aloxifene hydrochloride SA blets ibolone GREEN blets 4.1.2 Progestogens and progesterone receptor modulators	NICE MMC BNF emc	adults: amenorrhoea paeds: pubertal induction (3 rd line RESTRICTED Specialist Med. Consultant only NICE TA160 / TA161 3 rd line use oral
microgram tablets caloxifene hydrochloride SA blets ibolone GREEN blets -4.1.2 Progestogens and progesterone receptor modulators	NICE MMC BNF emc	adults: amenorrhoea paeds: pubertal induction (3 rd line RESTRICTED Specialist Med. Consultant only NICE TA160 / TA161 3 rd line use oral
microgram tablets caloxifene hydrochloride SA blets ibolone GREEN blets .4.1.2 Progestogens and progesterone receptor modulators bydrogesterone	NICE MMC BNF emco	adults: amenorrhoea paeds: pubertal induction (3 rd line RESTRICTED Specialist Med. Consultant only NICE TA160 / TA161 3 rd line use oral
biblets Fibolone GREEN A.1.2 Progestogens and progesterone receptor modulators Dydrogesterone biblets	NICE MMC BNF emc	adults: amenorrhoea paeds: pubertal induction (3 rd line RESTRICTED Specialist Med. Consultant only NICE TA160 / TA161 3 rd line use oral
microgram tablets Raloxifene hydrochloride SA sablets Tibolone GREEN sablets A.1.2 Progestogens and progesterone receptor modulators Dydrogesterone	NICE MMC BNF emco	adults: amenorrhoea paeds: pubertal induction (3 rd line RESTRICTED Specialist Med. Consultant only NICE TA160 / TA161 3 rd line use oral
microgram tablets Caloxifene hydrochloride SA Ablets ibolone GREEN blets A.1.2 Progestogens and progesterone receptor modulators bydrogesterone blets dedroxyprogesterone acetate	NICE MMC BNF emco	adults: amenorrhoea paeds: pubertal induction (3 rd line RESTRICTED Specialist Med. Consultant only NICE TA160 / TA161 3 rd line use oral


MHRA Drug Safety Update (Feb-21): Ulipristal acetate 5mg (Esmya): further restrictions due to risk of serious liver injury

MHRA Drug Safety Update (Aug-18): Esmya - risk of serious liver injury: new restrictions to use, requirements for LFT monitoring before, during & after treatment

MHRA Drug Safety Update (Mar-18): Esmya (ulipristal acetate) for uterine fibroids: do not initiate or re-start treatment; monitor LFT in current and recent users








Evenity ® injection

NICE MMC BNF emc



MHRA Drug Safety Update (Jan-20): Mecasermin (Increlex ▼): risk of benign and malignant neoplasia

MF1 Formulary V10.6 (June 2025)	Section 6	Endocrine System
Non-Formulary Items		GM <mark>M</mark> MG
Carbimazole (DNP)		in line with GMMMG
10mg; 15mg tablets	MMC BNF emc	
Chlorpropamide (DNP)		in line with GMMMG
ablets	BNF	Criterion 1
Fezolinetant		
/eoza® 45mg tablets	BNF emco	
//IHRA Drug Safety Update (Apr-25): Fezolinetant ▼ (Veoza): risk of liver injur	y; new recommendations to minimise risk	
Gliclazide (DNP)		in line with GMMMG
Modified-release tablets (e.g. Diamicron® MR)	BNF emco	Criterion 2
Hypurin® Bovine Isophane		Discontinued July 2017
sophane insulin	emc⊛	
Hypurin® Bovine Lente		Discontinued July 2017
nsulin zinc suspension	emc⊚	
Hypurin® Bovine Neutral		Discontinued July 2017
nsulin bovine	NICE emc®	
Liraglutide RED	TARKET WARRANT	Weight loss - MFT is not a commissioned weight management service. Not for initiation, only for patients initiated at NCA.
Saxenda® 6mg/mL pre-filled pen	NICE MMC BNF emc	
Lixisenatide		Discontinued June 2022 / December 2023
_yxumia® 10 microgram; 20microgram injection	MMC BNF emc	
Metformin hydrochloride (DNP)		in line with GMMMG
g immediate-release tablets	BNF emc®	Criterion 2
Nateglinide		Discontinued August 2020
ablets	MMC (BNF) (emc)	
Pen needles 8mm, 10mm, or 12mm in length (DNP)		in line with GMMMG
		Criterion 1
Pen needles costing in excess of £5 per 100 (DNP)		in line with GMMMG
		Criterion 3
Semaglutide RED		Weight loss - MFT is not a commissioned weight management service. Not for initiation, only for patients initiated at NCA
Wegovy® injection	NICE MMC BNF emc	
Sotagliflozin		Withdrawn August 2022
Zynquista ® 200mg tablets	NICE MMC emc®	
Tirzepatide (DNP)		Weight loss - MFT is not a commissioned weight management service. Not for initiation, only for patients initiated at NCA.
Mauriara ® injection	NICE BARRA COMP.	
Mounjaro ® injection	NICE MMC BNF EMC®	

Section 7: Obstetrics, gynaecology & urinary tract disorders

Supported by the formulary (click here)



7.1 Drugs used in Obstetrics

7.1.1 Prostaglandins & oxytocics

7.1.1.1 Drugs affecting the ductus arteriosus

7.1.2 Mifepristone

7.1.3 Myometrial relaxants

7.2 Treatment of vaginal & vulval conditions

7.2.1 Preparations for vaginal & vulval changes

7.2.2 Vaginal & vulval infections

7.3 Contraceptives

7.3.1 Combined hormonal contraceptives

Ethinylestradiol with Desogestrel

Ethinylestradiol with Gestodene

Ethinylestradiol with Levonorgestrel

Ethinylestradiol with Norelgestromin

Ethinylestradiol with Norethisterone

Ethinylestradiol with Norgestimate

Mestranol with Norethisterone

7.3.2 Progestogen-only contraceptives

7.3.2.1 Oral progestogen-only contraceptives

7.3.2.2 Parenteral progestogen-only contraceptives

7.3.2.3 Intra-uterine progestogen-only device

7.3.5 Emergency contraception

7.4 Drugs for genito-urinary disorders

7.4.1 Drugs for urinary retention

7.4.2 Drugs for urinary, enuresis & incontinence

7.4.3 Drugs used in urological pain

7.4.4 Bladder instillations & urological surgery

7.4.5 Drugs for erectile dysfunction

7.4.6 Drugs for premature ejaculation

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Long-acting reversible contraception (CG30)

Lower urinary tract symptoms (CG97)

Nocturnal enuresis - the management of bedwetting in children and young people (CG111)

Antenatal and postnatal mental health: clinical management and service guidance (CG192)

Heavy menstrual bleeding: assessment and management (NG88)

Urinary incontinence and pelvic organ prolapse in women: management (NG123)

Caesarean birth (NG192)

Antenatal care for uncomplicated pregnancies (NG201)

Inducing labour (NG207)

Intrapartum care for healthy women and babies (NG235)

Overactive bladder - mirabegron (TA290)

Pentosan polysulfate sodium for treating bladder pain syndrome (TA610)

Vibegron for treating symptoms of overactive bladder syndrome (TA999)


GMMMG Formulary


Formulary Homepage


Chapter 7: Obstetrics, gynaecology & urinary tract disorders


GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List









MF1 Formulary V10.6 (June 2025)	Section 7	Obs., Gynae urmary tract disorders
7.4 Drugs for genito-urinary disorde	rs	GM <mark>M</mark> MG
7.4.1 Drugs for urinary retention		NICE CG97
Alpha blockers		NICE CG111
		NICE NG123
Alfuzosin hydrochloride		
GREEN		
ablets	BNF emco	
Tamsulosin hydrochloride		, et
GREEN	(B)(K(F)	1 st line
capsules, tablets	MMC BNF emc	
7.4.2 Drugs for urinary, enuresis & incontinence		
Urinary incontinence		NICE NG123
Oxybutynin hydrochloride		, at
GREEN	BXX	1 st line in OAB
oral solution; patch; tablets	NICE MMC BNF emc	
Darifenacin hydrobromide		
GREEN		1 st line in OAB
ablets	NICE MMC BNF emc	
Tolterodine tartrate		48t
GREEN	IBNVIII	1 st line in OAB
capsules, tablets	NICE MMC BNF emco	
Solifenacin succinate		and
	(83)/(15	2 nd line in OAB
ablets	MMC BNF emc	
Duloxetine		
GREY GREEN		
capsules	MMC BNF emc	
Trospium chloride		RESTRICTED
GREEN	IBN IF	1 ^{RY} Care referral only
capsules; tablets	MMC BNF emc	
Mirabegron		RESTRICTED
GREEN		in line with TA290 / Paeds 3 rd line
rablets	NICE MMC BNF EMC®	
MHRA Drug Safety Update (Oct-15): Mirabegron (Betmiga ▼): risk of severe hyp		events
Vibegron		RESTRICTED
		in line with TA999
Obgemsa ® 75 mg tablets	NICE MMC BNF emc	
Nocturnal enuresis		
Amitriptyline hydrochloride		
GREN	ISJN 15 to observe	
oral solution; tablets (see also section 4.3.1)	BNF emc	
Desmopressin		RESTRICTED
SI	[83]K] [5] too charde en	Haematology Consultants only
njection; nasal spray; tablets (see also section 6.5.2)	MMC BNF emc	
7.4.3 Drugs used in urological pain		
Methionine ①		RESTRICTED
		resistant calcium phosphate lithiasis
ablets	emc	European Association of Urology
Pentosan polysulfate sodium		RESTRICTED
RED		Urology Cons. in line with NICE
capsules	NICE MMC BNF EMC	
MHRA Drug Safety Update (Sep-19): Elmiron (pentosan polysulfate sodium): rare	e risk of pigmentary maculopathy	
Potassium citrate GREEN OTC		
OIC .	IBUN IF for oblidate	
tablets	BNF emc	

7.4.4 Bladder instillations & urological surgery			
Chlorhexidine			
RED	(E)(X)	(F	
0.02% irrigation solution	BN	emc _®	
Dimethyl sulfoxide U			
50% solution		emc⊚	
Glycine			
1.5% irrigation solution	BN	emc _®	
Sodium chloride RED	[SUN]	15	
0.9% irrigation solution	BN	F emc⊚	
Sodium citrate RED	EN X		
3% irrigation solution Sodium hyaluronate	BN	emc _®	DESTRICTES
RED			RESTRICTED Urology Consultants only
Cystistat® 40mg/50mL bladder instillation	MMC	<u>emc</u> ⊚	
Sodium hyaluronate with sodium chondroitin sulfate			RESTRICTED Urology Consultants only
iAluRil® 800mg/50mL (1.6% w/v) / 1g/50mL (2% w/v) bladder instillation	MMC	<u>emc</u>	
7.4.5 Drugs for erectile dysfunction			
Alprostadil	(S)N for shillo	[5 ***	RESTRICTED Urology Consultants only
cream; injection; urethral sticks Aviptadil with phentolamine mesilate	MMCEN	F emc⊚	DESTRICTED
SI			RESTRICTED Urology Consultants only
Invicorp® injection	MMC BN	emc _®	
Sildenafil GREEN or RED PAH	[E] N	I.F.	RESTRICTED 1 ^{RY} Care referral only
injection; oral suspension; tablets (see also section 2.5.1)		emc _®	
MHRA Drug Safety Update (Nov-18): Sildenafil (Revatio & Viagra): reports of PPHN following in- Tadalafil	utero exposure in a clir	nical trial on intraute	-
GREEN OF RED PAH			RESTRICTED 1 ^{RY} Care referral only
tablets (see also section 2.5.1) Vardenafil	MMCEN	F emc⊚	DESTRICTES
varuenam			RESTRICTED 1 ^{RY} Care referral only
tablets	MMC BN	emc _®	
7.4.6 Drugs for premature ejaculation (DNP)			
NOT STOCKED			

Non-Formulary Items		Gм <mark>™</mark> мG
Dapoxetine hydrochloride (DNP)		in line with GMMMG
Priligy® 30mg; 60mg tablets	BNF emco	Criterion 1
Doxazosin (DNP)	SNI SNI	in line with GMMMG
img M/R tablets; 8mg tablets	BNF emco	Criterion 2
Licensed and off-label topical anaesthetics (DNP)		in line with GMMMG
		Criterion 1
lild cystitis (2-3 days)		in line with GMMMG / NHSE
g. Potassium citrate mixture or sachets, cranberry products		
Tadalafil (DNP)		in line with GMMMG
2.5mg tablets	BNF emco	Criterion 2
Tamsulosin with dutasteride		in line with GMMMG
400microgram / 500microgram hard capsules	BNF emc	Criterion 1

Section 8: Malignant disease & immunosuppression

Supported by the formulary (click here)



8.1 Cytotoxic drugs

Drugs for cytotoxic-induced side-effects

- 8.1.1 Alkylating drugs
- 8.1.2 Anthracyclines & other cytotoxic antibiotics
- 8.1.3 Antimetabolites
- 8.1.4 Vinca alkaloids & etoposide
- 8.1.5 Other antineoplastic drugs

8.2 Drugs affecting the immune response

- 8.2.1 Antiproliferative immunosuppressants
- 8.2.2 Corticosteroids & other immunosuppressants
- 8.2.3 Anti-lymphocyte monoclonal antibodies
- 8.2.4 Other immunomodulating drugs

8.3 Sex hormones & hormone antagonists in malignant disease

- 8.3.1 Oestrogens
- 8.3.2 Progestogens
- 8.3.3 Androgens
- 8.3.4 Hormone Antagonists
 - 8.3.4.1 Breast Cancer
 - 8.3.4.2 Gonadorelin analogues & gonadotrophin-releasing hormone antagonists
 - 8.3.4.3 Somatostatin analogues

8.4 Miscellaneous preparations

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

NICE Guidance

Advanced breast cancer (CG81)

Familial breast cancer (CG164)

Hepatitis B (chronic) (CG165)

Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)

Selumetinib for treating symptomatic & inoperable plexiform neurofibromas associated with type 1 neurofibromatosis (HST20)

Early and locally advanced breast cancer: diagnosis and management (NG101)

Lung cancer: diagnosis and management (NG122)

Prostate cancer: diagnosis and management (NG131)

Colorectal cancer (NG151)

Temozolomide for malignant glioma (TA23)

Leukaemia (lymphocytic) - fludarabine (TA29)

Trastuzumab for advanced breast cancer (TA34)

Paclitaxel for ovarian cancer (TA55)

Capecitabine and Tegafur Uracil for Colorectal Cancer (TA61)

Imatinib for chronic myeloid leukaemia (TA70) (partially updated by TA425 & TA426)

Hepatitis C: Chronic (TA75) (extended by TA106 - partially updated by TA200 & TA300)

Gastrointestinal stromal tumours - imatinib (TA86) (partially updated by TA209)

Hepatitis B: Chronic (TA96) (partially updated by CG165)

Colon cancer (adjuvant) - capecitabine and oxaliplatin (TA100)

Docetaxel for prostate cancer (hormone-refractory) (TA101)

Hepatitis C: Peginterferon & Ribavirin (TA106) (partially updated by TA200 & TA300)

Paclitaxel for early breast cancer (TA108)

Docetaxel for early breast cancer (TA109)

Gemcitabine for Breast Cancer (TA116)

Bevacizumab & Cetuximab in metastatic colorectal cancer (TA118) (partially updated by TA242)

Leukaemia (lymphocytic) - fludarabine (TA119)

Carmustine implants and temozolomide for gliomo (newly diagnosed & high grade) (TA121)

Pemetrexed for lung cancer (non small cell) (TA124)

Multiple sclerosis - natalizumab (TA127)

Bortezomib for relapsed multiple myeloma (TA129)

Pemetrexed for mesothelioma (TA135)

Rituximab for follicular non-Hodgkin's lymphoma (TA137)

Head and neck cancer - cetuximab (TA145)

Renal cell carcinoma - sunitinib (TA169)

Lenalidomide - multiple myeloma (TA171)

Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)

Cetuximab for the first-line treatment of metastatic colorectal cancer (TA176)

Renal Cell Carcinoma (TA178)

Sunitinib for gastrointestinal stromal tumours (TA179)

Pemetrexed for lung cancer (non-small cell) - first line treatment (TA181)

Cervical cancer (recurrent) - topotecan (TA183)

Lung cancer (small cell) - topotecan (TA184)

Soft tissue sarcoma - trabectedin (TA185)

Lung cancer (non-small-cell) - pemetrexed (maintenance) (TA190)

Gastric cancer (advanced) - capecitabine (TA191)

Lung cancer (non-small-cell, first line) - gefitinib (TA192)

Leukaemia (chronic lymphocytic, relapsed) - rituximab (TA193)

Gastrointestinal stromal tumours - imatinib (adjuvant) (TA196)

Hepatitis C - peginterferon alfa and ribavirin (TA200) (read in conjunction with TA75 & TA106)

Gastric cancer (HER2-positive metastatic) - trastuzumab (TA208)

Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib (TA209) (part review of TA86)

Colorectal cancer (metastatic) - bevacizumab (TA212)

Breast cancer - bevacizumab (in combination with a taxane) (TA214) (replaces TA147)

Renal cell carcinoma (1st line metastatic) - pazopanib (TA215)

Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (TA216)

Myelodysplastic syndrome - azacitidine (TA218)

Lymphoma (follicular non-Hodgkin's) - rituximab (TA226)

Multiple myeloma (1st line) - bortezomib and thalidomide (TA228)

Osteosarcoma - mifamurtide (TA235)

Follicular lymphoma - rituximab (review TA110) (TA243)

Multiple sclerosis (relapsing-remitting) - fingolimod (TA254)

Melanoma (stage III or IV) - ipilimumab (TA268)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib (TA269)

Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine (TA272)

Bevacizumab in combination with paclitaxel & carboplatin for 1st line treatment of advanced ovarian cancer (TA284)

Ovarian, fallopian tube & primary peritoneal cancer - bevacizumab (TA285)

Hepatitis C (children and young people) - peginterferon alfa & ribavirin (TA300)

Multiple sclerosis (relapsing) - teriflunomide (TA303)

Lymphoma (non Hodgkin's, relapsed, refractory) - pixantrone monotherapy (TA306)

Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) (TA308)

Multiple myeloma - bortezomib (induction therapy) (TA311)

Multiple sclerosis (relapsing-remitting) - alemtuzumab (TA312)

pilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)

Dimethyl fumarate for treating relapsing-remitting multiple sclerosis (TA320)

Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA321)

Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5g cytogenetic abnormality (TA322)

Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of TA196) (TA326)

Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333)

Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)

Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non small cell lung cancer (TA347)

Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)

Idelalisib for treating chronic lymphocytic leukaemia (TA359)

Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)

Bortezomib for previously untreated mantle cell lymphoma (TA370)

Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374)

Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)

Nintedanib for treating idiopathic pulmonary fibrosis (TA379)

Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)

Olaparib forovarian, fallopian tube and peritoneal cancer (TA381)

Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)

Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)

Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)

Topotecan, PLDH, paclitaxel, trabectedin & gemcitabine for recurrent ovarian cancer (TA389)

Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)

Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (TA395)

Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)

Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)

Bosutinib for previously treated chronic myeloid leukaemia (TA401)

Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402)

Degarelix for treating advanced hormone-dependent prostate cancer (TA404)

Trifluridine-tipiracil for previously treated metastatic colorectal cancer (TA405)

Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA406)

Pegaspargase for treating acute lymphoblastic leukaemia (TA408)

Talimogene laherparepyec for treating unresectable metastatic melanoma (TA410)

Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)

Nivolumab for previously treated advanced renal cell carcinoma (TA417)

Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)

Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA422)

Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)

Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)

Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)

Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)

Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)

Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)

Everolimus for advanced renal cell carcinoma after previous treatment (TA432)

Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)

Everolimus & sunitinib for treating unresectable or metastatic neuroendocrine tumours (TA449)

Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia (TA450)

Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)

Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)

Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)

Cabozantinib for previously treated advanced renal cell carcinoma (TA463)

Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (replaces TA172) (TA473)

Sorafenib for treating advanced hepatocellular carcinoma (replaces TA189) (TA474)

Paclitaxel with gemcitabine for untreated metastatic pancreatic cancer (replaces TA360) (TA476)

Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (TA478)

Immunosuppressive therapy for kidney transplant in adults (replaces TA85) (TA481)

Immunosuppressive therapy for kidney transplant in children and young people (replaces TA99) (TA482)

Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)

Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)

Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)

Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA490)

Ibrutinib for treating Waldenstrom's macroglobulinaemia (TA491)

Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492)

Cladribine tablets for treating relapsing-remitting multiple sclerosis (TA493)

Palbociclib for previously untreated, locally advanced or metastatic breast cancer (TA495)

Ribociclib for previously untreated, locally advanced or metastatic breast cancer (TA496)

Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)

Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)

Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)

Ibrutinib for treating relapsed or refractory mantle cell lymphoma (TA502)

Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA503)

Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)

Tivozanib for treating advanced renal cell carcinoma (TA512)

Obinutuzumab for untreated advanced follicular lymphoma (TA513)

Regorafenib for previously treated advanced hepatocellular carcinoma (TA514)

Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (replaces TA250) (TA515)

Cabozantinib for treating medullary thyroid cancer (TA516)

Avelumab for treating metastatic Merkel cell carcinoma (TA517)

Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma (TA519)

Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)

Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA522)

Midostaurin for untreated acute myeloid leukaemia (TA523)

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (replaces TA446) (TA524)

Atezolizumab for treating locally advanced or metastatic urothelial carcinoma (TA525)

Arsenic trioxide for treating acute promyelocytic leukaemia (TA526)

Beta interferons and glatiramer acetate for treating multiple sclerosis (replaces TA32) (TA527)

Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA528)

Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer (TA530)

Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)

Ocrelizumab for treating relapsing-remitting multiple sclerosis (TA533)

Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)

Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)

Dinutuximab beta for treating neuroblastoma (TA538)

Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)

Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)

Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia (TA541)

Cabozantinib for untreated advanced renal cell carcinoma (TA542)

Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)

Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (TA545)

Padeliporfin for untreated localised prostate cancer (TA546)

Vandetanib for treating medullary thyroid cancer (TA550)

Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)

Liposomal cytarabine-daunorubicin for untreated acute myeloid leukaemia (TA552)

Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (TA553)

Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)

Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma (TA559)

Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)

Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562)

Abemaciclib for previously untreated, locally advanced or metastatic breast cancer (TA563)

Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)

Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (TA571)

Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)

Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA579)

Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)

Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)

Ocrelizumab for treating primary progressive multiple sclerosis (TA585)

Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)

Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)

Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity (TA589)

Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA593)

Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer (TA598)

Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA600)

Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA611)

Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer (TA612)

Cladribine for treating relapsing-remitting multiple sclerosis (TA616)

Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619)

Peginterferon beta-1a for treating relapsing-remitting multiple sclerosis (TA624)

Lenalidomide with rituximab for previously treated follicular lymphoma (TA627)

Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)

Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (replacing TA472) (TA629)

Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)

Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632)

Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (TA638)

Atezolizumab for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer (TA639)

Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640)

Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (TA641)

Gilteritinib for treating relapsed or refractory acute myeloid leukaemia (TA642)

Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)

Entrectinib for treating NTRK fusion-positive solid tumours (TA644)

Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)

Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma (TA649)

Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)

Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (replacing TA416) (TA653)

Osimertinib for untreated EGFR mutation-positive NSCLC (replacing TA621) (TA654)

Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy (TA655) Carfilzomib for previously treated multiple myeloma (replacing TA457) (TA657)

Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer (TA660)

Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (TA661)

Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)

Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)

Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer (TA668)

Brigatinib for ALK-positive advanced NSCLC that has not been previously treated with an ALK inhibitor (TA670)

Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma (TA677)

Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma (TA680)

Pembrolizumab with pemetrexed for untreated, metastatic, non-squamous NSCLC (replacing TA557) (TA683)

Nivolumab for adjuvant treatment of completely resected melanoma (replacing TA558) (TA684)

Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA687)

Acalabrutinib for treating chronic lymphocytic leukaemia (TA689)

Avelumab for untreated metastatic Merkel cell carcinoma (TA691)

Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer (TA693)

Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (TA695)

Ofatumumab for treating relapsing multiple sclerosis (TA699)

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer (TA704)

Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705)

Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer (TA707)

Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA709)

Enzalutamide for treating hormone-sensitive metastatic prostate cancer (TA712)

Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy (TA713)

Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with ... (TA716)

Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)

Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA721)

Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA722)

Abemaciclib for treating hormone receptor-positive, HER2-negative advanced breast cancer (updates & replaces TA579) (TA725)

Midostaurin for treating advanced systemic mastocytosis (TA728)

Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck (TA736)

Pembrolizumab for untreated advanced oesophageal & gastro-oesophageal junction cancer (TA737)

Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable (TA739)

Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer (TA740)

Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA741)

Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer (TA746)

Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)

Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome (TA754)

Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763)

Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA765)

Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)

Ponesimod for treating relapsing-remitting multiple sclerosis (TA767)

Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA770)

Pembrolizumab for relapsed or refractory classical Hodgkin lymphoma after SCT or at least 2 previous therapies (TA772)

Dostarlimab for previously treated advanced or recurrent endometrial cancer.... (TA779)

Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)

Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (TA781)

Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783)

Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA784)

Tucatinib with trastuzumab & capecitabine for treating HER2-positive advanced breast cancer…. (TA786)

Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA787)

Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer.... (TA788)

Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations (TA789)

Diroximel fumarate for treating relapsing-remitting multiple sclerosis (TA794)

Ibrutinib for treating Waldenstrom's macroglobulinaemia (replacing TA491) (TA795)

Venetoclax for treating chronic lymphocytic leukaemia (replacing TA487) (TA796)

Durvalumab for maintenance treatment of unresectable NSCLC after platinum-based chemoradiation (replacing TA578) (TA798)

Pembrolizumab (plus chemo) for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer (TA801)

Cemiplimab for treating advanced cutaneous squamous cell carcinoma (updates & replaces TA592) (TA802) Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease (TA809)

Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer (TA810)

Praisetinib for treating RET fusion-positive advanced non-small-cell lung cancer (TA812)

Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)

Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer (TA816)

Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)

Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)

Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies (TA819)

Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA823)

Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis (TA825)

Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy (TA827)

Pembrolizumab for adjuvant treatment of renal cell carcinoma (TA830)

Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)

Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA836)

Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)

Cabozantinib for previously treated advanced hepatocellular carcinoma (TA849)

Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer (TA851)

Trifluridine–tipiracil for metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma (replacing TA669) (TA852)

Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced NSCLC after platinum-based chemotherapy (TA855)

Nivolumab for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma (TA857)

Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma (TA858)

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer (TA862)

Nintedanib for treating idiopathic pulmonary fibrosis when FVC is above 80% predicted (partially replaces TA379) (TA864)

Nivolumab for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (TA865)

Regorafenib for previously treated metastatic colorectal cancer (TA866)

lxazomib with lenalidomide & dexamethasone for treating relapsed or refractory multiple myeloma (replacing TA505) (TA870)

Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma (replacing TA559) (TA872)

Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma (TA874)

Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer (TA876)

Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)

Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy (TA886)

Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA887)

Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia (TA891)

Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia...(TA893)

Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma... (TA895)

Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (updates & replaces TA573) (TA897)

Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer (TA898)

Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer (TA903)

Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)

Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA908)

Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer (TA911)

Pembrolizumab For treating tumours with high microsatellite instability (MSI) or mismatch repair (MMR) deficiency (TA914)

Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a SCT is unsuitable (TA917)

Ruxolitinib for treating polycythaemia vera (TA921)

Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA927)

Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)

Targeted-release budesonide for treating primary IgA nephropathy (TA937)

Pembrolizumab for persistent, recurrent or metastatic cervical cancer (replaces TA885) (TA939)

Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer (TA944)

Olaparib with bevacizumab for treatment of advanced high-grade epithelial ovarian, fallopian tube or 1ry peritoneal cancer (TA946)

Loncastuximab tesirine for treating relapsed or refractory DLBCL and HGBCL after 2 or more systemic treatments (TA947)

lvosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments (TA948) Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over (TA949)

Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)

Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)

Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA954)

Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)

Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis (TA959)

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer (TA962)

Dostarlimab with platinum-based chemo for advanced / recurrent endometrial cancer with MSI-H or MMR deficiency (TA963)

Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (TA964)

Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over (TA967)

Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments (TA970)

Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (TA974)

Tisagenlecleucel for treating relapsed or refractory B-cell ALL in people 25 years and under (updates & replaces TA554) (TA975)

Dabrafenib for treating BRAF V600E mutation-positive glioma in children & young people aged 1 year & over (TA977)

lvosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation (TA979)

Pembrolizumab for untreated locally advanced unresectable or metastatic HER2-positive gastric or GOJ adenocarcinoma (TA983)

Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (TA992)

Relugolix for treating hormone-sensitive prostate cancer (TA995)

Pembrolizumab with platinum- and fluoropyrimidine-based chemo for untreated advanced HER2-negative gastric or GOJA (TA997)

Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment (TA1001)

Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA1005)

Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA1007)

Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments (TA1008)

Belzutifan for treating tumours associated with von Hippel-Lindau disease (TA1011)

Avapritinib for treating advanced systemic mastocytosis (TA1012)

Quizartinib for treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia (TA1013)

Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer (TA1014)

Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1015)

Pembrolizumab before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable NSCLC (TA1017)

Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (updates & replaces TA756) (TA1018)

Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (updates & replaces TA529) (TA1021) Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1023)

Ublituximab for treating relapsing multiple sclerosis (TA1025)

Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for resectable NSCLC (TA1030)

Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy (TA1034)

Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer (TA1036)

Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1037)

Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug... (TA1038)

Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug... (TA1039)

Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy (TA1040)

Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer (TA1041)

Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA1042)

Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (TA1043)

Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over (TA1044)

Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma (TA1048)

Blinatumomab for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-cell ALL (TA1049) Cladribine for treating active relapsing forms of multiple sclerosis (TA1053)

Ruxolitinib for treating acute GvHD that responds inadequately to corticosteroids in people 12 years and over (TA1054)

Rucaparib for treatment of advanced ovarian, fallopian tube & peritoneal cancer... (TA1055) Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma (TA1059)

Osimertinib for untreated EGFR mutation-positive advanced NSCLC (TA1060)

Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor (TA1062)

Capivasertib for treating hormone receptor-positive HER2-negative advanced breast cancer (TA1063)

Dostarlimab for treating primary advanced or recurrent endometrial cancer with MSI-H or dMMR (TA1064)

<u>Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with MSI-H or dMMR (TA1065)</u>


GMMMG Formulary

Formulary Homepage

Chapter 8: Malignant disease & immunosuppression

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List



Mitoxantrone infusion **Pixantrone** infusion 8.1.3 Antimetabolites **NICE NG151 Azacitidine** RESTRICTED RED EE **Haematology Consultants only** iniection PBRX NICE MMC BNF CMC Capecitabine RED NHS England tablets NICE MMC BNF emc MHRA Drug Safety Update (Oct-20): 5-fluorouracil (IV), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at risk of severe & fatal toxicity MHRA Drug Safety Update (Dec-14): Capecitabine: risk of severe skin reactions - discontinue treatment Cladribine **RESTRICTED** RED ££ **Haematology Consultants only** blueteq PBRX NICE MMC BNF EMC® infusion; injection MHRA Drug Safety Update (Mar-22): Cladribine (Mavenclad): new advice to minimise risk of serious liver injury MHRA Drug Safety Update (Dec-17): Cladribine (Litak, Leustat) for leukaemia: reports of PML; stop treatment if PML is suspected Clofarabine **RESTRICTED** RED E **Haematology Consultants only** blueteq PbR X infusion BNF emce Cytarabine **RESTRICTED Haematology Consultants only** niection MMC BNF emc Daunorubicin with cytarabine RESTRICTED **Haematology Consultants only** blueteq Vyxeos® 100mg/44mg infusion PBRX NICE MMC BNF CMC Fludarabine phosphate **RESTRICTED** RED **Haematology Consultants only** injection; tablets NICE BNF emc **Fluorouracil RESTRICTED** RED **Haematology Consultants only** PbR X NICE injection BNF emc® MHRA Drug Safety Update (Oct-20): 5-fluorouracil (IV), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at risk of severe & fatal toxicity Gemcitabine RESTRICTED RED **Haematology Consultants only** PbR X NICE BNF emc® RED oral suspension; tablets (see also section 1.5.3) BNF emc MHRA Drug Safety Update (May-25): Thiopurines and intrahepatic cholestasis of pregnancy Methotrexate

infusion Mercaptopurine

infusion; injection; oral solution; tablets (see sections 1.5.3, 10.1.3 & 13.5.3) MMC BNF emc

MHRA Drug Safety Update (Aug-23): Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions

Pemetrexed **RESTRICTED** Respiratory

RED ££ Consultants only in line with TA402 blueteq

PBRX NICE MMC BNF CMC 8.1.4 Vinca alkaloids & etoposide

Etoposide RESTRICTED **Haematology Consultants only**

capsules; infusion emc • Vinblastine sulfate **RESTRICTED**

Haematology Consultants only injection Vincristine sulfate RESTRICTED

Haematology Consultants only BNF emc

RED ££ blueteq infusion PBRX NICE MMC BNF CMC Arsenic trioxide


8.1.5 Other antineoplastic drugs


Acalabrutinib

Haematology Consultants only

RESTRICTED Haem. Consultants only / in line with NICE TA526 / NHSE blueteq PBRX NICE MMC BNF CMC infusion

RESTRICTED







MHRA Drug Safety Update (Jan-22): Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error

PBRX NICE MMC BNF emc

PBRX NICE MMC BNF emc

blueteq

Infusion


Cabazitaxel

RED EE

Jevtana® Infusion

RESTRICTED

Haematology Consultants only



BCG bladder instillationBacillus Calmette-Guérin

OncoTICE® bladder instillation

Bacillus Calmette-Guérin

BCG-medac® intravesical suspension

RESTRICTEDSpecialist use only

RESTRICTED
Specialist use only

BNF emc

MMC BNF emc



PBRX NICE MMC BNF emc

blueteq

line with NICE TA303


NOT STOCKED

RESTRICTED Haematology **Consultants only**

capsules PBRX NICE MMC BNF emc MHRA Drug Safety Update (May-20): Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19)

MHRA Drug Safety Update (Dec-15): Thalidomide: reduced starting dose in patients older than age 75 years

MHRA Drug Safety Update (May-13): Thalidomide: risk of second primary malignancies



NEW RESTRICTIONS on puberty blockers - Department of Health and Social Care (29 May 2024)

line with NICE

bluetea





Section 9: Nutrition & blood

Supported by the formulary (click here)



9.1 Anaemias and some other blood disorders

- 9.1.1 Iron deficiency anaemias
- 9.1.2 Drugs used in megaoblastic anaemias
- 9.1.3 Drugs used in hypoplastic, haemolytic & renal anaemias
- 9.1.4 Drugs used in autoimmune thrombocytopenic purpura
- 9.1.6 Drugs used in neutropenia
- 9.1.7 Drugs used to mobilise stem cells
- 9.1.8 Haemophilia

9.2 Fluids and electrolytes

- 9.2.1 Oral preparations for fluid & electrolyte imbalance
- 9.2.2 Parenteral preparations for fluid & electrolyte imbalance
- 9.3 Intravenous nutrition

9.4 Oral nutrition

9.4.1 Nutrition in special diets

9.5 Minerals

- 9.5.1 Calcium and magnesium
- 9.5.2 Phosphorus
- 9.5.3 Fluoride
- 9.5.4 Zinc

9.6 Vitamins

- 9.6.1 Vitamin A
- 9.6.2 Vitamin B group
- 9.6.3 Vitamin C (Ascorbic acid)
- 9.6.4 Vitamin D
- 9.6.5 Vitamin E (Tocopherols)
- 9.6.6 Vitamin K
- 9.6.7 Multivitamin preparations

9.7 Bitters & tonics

9.8 Metabolic disorders

- 9.8.1 Drugs used in metabolic disorders
- 9.8.2 Acute porphyrias

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)

Nutrition support in adults (CG32)

Coeliac disease: recognition, assessment and management (NG20)

Chronic kidney disease: assessment and management (NG203)

Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)

Migalastat for treating Fabry disease (HST4)

Eliglustat for treating type 1 Gaucher disease (HST5)

Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)

Elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19)

Asfotase alfa for treating paediatric-onset hypophosphatasia (replacing HST6) (HST23)

Lumasiran for treating primary hyperoxaluria type 1 (HST25)

Hyperparathyroidsim - cinacalcet (TA117)

Thrombocytopenic purpura - romiplostim (TA221)

Thrombocytopenic purpura - eltrombopag (TA293)

Erythropolesis-stimulating agents (epoetin & darbepoetin) for treating anaemia in chemotherapy (TA323)

Etelcalcetide for treating secondary hyperparathyroidism (TA448)

Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)

Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)

Patiromer for treating hyperkalaemia (TA623)

Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA626)

Caplacizumab for treating acute acquired thrombotic thrombocytopenic purpura (TA667)

Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (TA698)

Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)

Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)

Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (TA778)

Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)

Avalglucosidase alfa for treating Pompe disease (TA821)

Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)

Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)

Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease (TA912)

Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)

lptacopan for treating paroxysmal nocturnal haemoglobinuria (TA1000)

Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over (TA1003)

Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (TA1010)

Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over (TA1019)

Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease (TA1035)


GMMMG Formulary


Formulary Homepage


Chapter 9: Nutrition & Blood


GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List









Bicarbonate and lactate		
Sodium bicarbonate		
1.26%, 2.74%, 4.2% & 8.4% injection; infusion	BNF emco	
Sodium lactate compound		
•	EXVID	
(Hartmann's solution) infusion	BNF emc	
Water		
Water for Injections		
•		
injection	emc⊚	
9.2.2.2 Plasma & plasma substitutes	<u>emo</u>	
Dextran		
Dextran 40 - 10% in sodium chloride 0.9% infusion	emc ⊚	
Dextrose Acid Citrate ACDA	CINO	
2000 7000 7000 7027		
solution		
Gelatin	<u>emc</u> ⊚	
Geraum		
	ES N I I I I I I I I I I I I I I I I I I	
Gelofusine® infusion	BNF emc	

9.3 Intravenous nutrition

BNF








Prescribers should seek advice from the MFT Nutrician Support Team (pager service 07659 526240) or the Dietetic Support Teams (General x64668; Renal x64478; Gastro x65781)

NICE CG32

9.4 Oral nutrition			GM <mark>M</mark> MG
Prescribers should seek advice from the MFT Nutrician Support Team (pager service 07659 526240) or the Dietetic Support Teams (General x64668; Renal x64478; Gastro x65781)			NICE CG32
9.4.1 Nutrition in special diets Sapropterin dihydrochloride			RESTRICTED
RED (E)	(B))) for the	<u>blue</u> teq	Tetrahydrobiopterin deficiency
Kuvan® 100mg soluble tablets	MMC (BN	F emc⊕	England
LaBiNIC® probiotic drops			RESTRICTED
			prevention of NEC
LaBiNIC® probiotic drops	MMC	emc⊛	









9.6.6 Vitamin K	
Phytomenadione	
GREEN	F N F
Konakion® MM & Konakion® MM Paediatric injection	MMC BNF emc
Menadiol sodium phosphate	
GREEN	F N F
oral solution; tablets	MMC BNF emc
9.6.7 Multivitamin preparations	
Vitamins B,C	RESTRICTED
Renavit® tablets	MMC BNF emc
Vitamins A,D,E,K	RESTRICTED
GREY SI	Paediatric CF patients
Paravit-CF® capsules; liquid	MMC BNF emc


9.7 Bitters & tonics



Mixtures containing simple and aromatic bitters are traditional remedies for loss of appetite; there is no evidence to support their use







Section 10: Musculoskeletal & joint diseases

Supported by the formulary (click here)



10.1 Drugs used in rheumatic diseases & gout

10.1.1 Non-steroidal anti-inflammatory drugs

10.1.2 Corticosteroids

10.1.3 Drugs that suppress the rheumatic disease process

Gold

Penicillamine

Antimalarials

Drugs affecting the immune response

Cytokine modulators

10.1.4 Gout and cytotoxic induced hyperuricaemia

10.1.5 Other drugs for rheumatic diseases

10.2 Drugs used in neuromuscular disorders

10.2.1 Drugs that enhance neuromuscular transmission

10.2.2 Skeletal muscle relaxants

Nocturnal leg cramps

10.2.3 Drugs used in neuromuscular disorders

10.3 Drugs for the relief of soft-tissue inflammation

10.3.1 Enzymes

10.3.2 Rubefacients & other topical antirheumatics

10.4 Miscellaneous preparations

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Biosimilar Medicines (KTT15)

Rheumatoid arthritis in adults: management (NG100)

Osteoarthritis in over 16s: diagnosis and management (NG226)

Onasemnogene abeparvovec for treating spinal muscular atrophy (HST15)

Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)

Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (replacing HST3) (HST22)

Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy (partial update of HST15) (HST24)

Hyperuricaemia - febuxostat (TA164)

Psoriasis - ustekinumab (TA180)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor (TA195)

Psoriatic arthritis - etanercept, infliximab and adalimumab (TA199)

Psoriatic arthritis - golimumab (TA220)

Rheumatoid arthritis (after the failure of previous DMARDs) - golimumab (TA225)

Arthritis (juvenile idiopathic, systemic) - tocilizumab (TA238)

Rheumatoid arthritis - tocilizumab (rapid review TA198) (TA247)

Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) (TA308)

Ustekinumab for treating active psoriatic arthritis (rapid review of TA313) (TA340)

Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)

Adalimumab, etanercept, infliximab, certolizumab, golimumab, tocilizumab & abatacept for rheumatoid arthritis (TA375)

TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor (TA415)

Apremilast for treating active psoriatic arthritis (TA433)

Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)

Collagenase clostridium histolyticum for treating Dupuytren's contracture (TA459)

Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)

Baricitinib for moderate to severe rheumatoid arthritis (TA466)

Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee (replaces TA89) (TA477)

Tofacitinib for moderate to severe rheumatoid arthritis (TA480)

Sarilumab for moderate to severe rheumatoid arthritis (TA485)

Lesinurad for treating chronic hyperuricaemia in people with gout (TA506)

Autologous chondrocyte implantation using chondrosphere for symptomatic articular cartilage defects of the knee (TA508)

Tocilizumab for treating giant cell arteritis (TA518)

Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)

Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)

Tofacitinib for moderately to severely active ulcerative colitis (TA547)

Nusinersen for treating spinal muscular atrophy (TA588)

Upadacitinib for treating severe rheumatoid arthritis (TA665)

Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)

Anakinra for treating Still's disease (TA685)

Adalimumab, etanercept, infliximab & abatacept for treating moderate RA after conventional DMARDs have failed (TA715)

Ixekizumab for treating axial spondyloarthritis in adults (TA718)

Secukinumab for treating non-radiographic axial spondyloarthritis in adults (TA719)

Tofacitinib for treating juvenile idiopathic arthritis (TA735)

Upadacitinib for treating moderate rheumatoid arthritis (TA744)

Belimumab for treating active autoantibody-positive systemic lupus erythematosus (replaces TA397) (TA752)

Risdiplam for treating spinal muscular atrophy (TA755)

Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)

Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (replacing TA711) (TA815)

Upadacitinib for treating active ankylosing spondylitis (TA829)

Upadacitinib for treating active non-radiographic axial spondyloarthritis (TA861)

Bimekizumab for treating axial spondyloarthritis (TA918)

Tofacitinib for treating active ankylosing spondylitis (TA920)

Efgartigimod for treating antibody-positive generalised myasthenia gravis (TA1069)

GMMMG Formulary

Formulary Homepage


Chapter 10: Musculoskeletal & Joint Diseases

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List


Phenylbutazone

100mg; 200mg tablets




RESTRICTED Specialist use only, ankylosing spondylitis

BNF emc®



MHRA Drug Safety Update (Sep-20): Methotrexate once-weekly for autoimmune diseases: new measures to reduce risk of fatal overdose




Long-term control of gout **Allopurinol** GREEN Febuxostat GREEN Rheumatology Consultants only NICE MMC BNF emc tablets MHRA Drug Safety Update (May-23): Febuxostat: updated advice for the treatment of patients with a history of major cardiovascular disease


MHRA Drug Safety Update (Jun-12): Febuxostat (Adenuric ▼): stop treatment if signs or symptoms of serious hypersensitivity Hyperuricaemia associated with cytotoxic drugs Rasburicase

RESTRICTED RED ££ **Haematology Consultants only** blueteq Fasturtec® infusion PbR X MMC BNF emc 10.1.5 Other drugs for rheumatic diseases

MHRA Drug Safety Update (Jul-19): Febuxostat: increased risk of CV death and all-cause mortality in clinical trial in patients with a history of major CV disease

NICE CG177 **NICE TA477 NICE TA508**







Non-Formulary Items		GM <mark>M</mark> MG
Efgartigimod alfa	bluetec	MFT not a commissioned centre Patients referred to NCA
Vyvgart® injection; infusion	PBR X NICE MMC BNF CMC	
Glucosamine (DNP)		in line with GMMMG
vith or without chondroitin	BNF	
Hyaluronan injections (DNP)		in line with GMMMG
njection including hyaluronan and sodium hyaluronate	BNF	
Naproxen with esomeprazole		in line with NICE / GMMMG
	BNF emc	
Satralizumab (DNP)		in line with NICE / GMMMG
Enspryng® injection	NICE BNF @MC@	
Sodium aurothiomalate		Discontinued June 2019
njection	BNF emc	

Section 11: Eye

Supported by the formulary (click here)



11.3 Anti-infective eye preparations

- 11.3.1 Antibacterials
- 11.3.3 Antivirals

11.4 Corticosteroid & other anti-inflammatory preparations

- 11.4.1 Corticosteroids
- 11.4.2 Other anti-inflammatory preparations
- 11.5 Mydriatics & cycloplegics

11.6 Treatment of glaucoma

Beta-blockers

Prostaglandin analogues and prostamides

Combination products (prostaglandin analogue with beta-blocker)

Combination products (prostaglandin analogue with Rho kinase inhibitor)

Sympathomimetics

Carbonic anhydrase inhibitors

Miotics

11.7 Local anaesthetics

11.8 Miscellaneous ophthalmic preparations

- 11.8.1 Tear deficiency, ocular lubricants & astringents
- 11.8.2 Ocular diagnostic & peri-operative preparations & photodynamic treatment
- 11.8.3 Other preparations

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Glaucoma: diagnosis and management (NG81)

Age-related macular degeneration (NG82)

Diabetic retinopathy: management and monitoring (NG242)

Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)

Macular degeneration (age related) ranibizimab & pegaptanib (TA155)

Macular oedema (retinal vein occlusion) - dexamethasone (TA229)

Macular oedema (diabetic) - ranibizumab (TA274)

Macular oedema (retinal vein occlusion) - ranibizumab (TA283)

Macular degeneration (wet age-related) - aflibercept (1st line) (TA294)

Choroidal neovascularisation (pathological myopia) - ranibizumab (TA298)

Macular oedema (central retinal vein occlusion) - aflibercept solution for injection (TA305)

Aflibercept for treating diabetic macular oedema (TA346)

Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears (TA369)

Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)

Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)

Holoclar for treating limbal stem cell deficiency after eye burns (TA467)

Aflibercept for treating choroidal neovascularisation (TA486)

Cenegermin for treating neurotrophic keratitis (TA532)

Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uvetitis (TA590)

Brolucizumab for treating wet age-related macular degeneration (TA672)

Faricimab for treating diabetic macular oedema (TA799)

Faricimab for treating wet age-related macular degeneration (TA800)

Brolucizumab for treating diabetic macular oedema (TA820)

Dexamethasone intravitreal implant for treating diabetic macular oedema (replacing TA349) (TA824)

Fluocinolone acetonide intravitreal implant for treating chronic DMO (updates & replaces TA301 / TA613) (TA953)

Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion (TA1004)

Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension (TA1009)

Bevacizumab gamma for treating wet age-related macular degeneration (TA1022)

Tebentafusp for treating advanced uveal melanoma (TA1027)

GMMMG Formulary

Formulary Homepage


Chapter 11: Eye


GMMMG Adult Red/Amber/Green; DNP and Grey Drug List


GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List

11.3 Anti-infective eye preparations	GM <mark>™</mark> MG
11.3.1 Antibacterials	
Chloramphenicol	
GREEN OTC (DNP)	
0.5% eye drops, 1% eye ointment ((DNP) bacterial conjunctivitis)	
MHRA Drug Safety Update (Jul-21): Chloramphenicol eye drops containing borax or boric acid buffers: use in children younger than 2	
Fusidic acid (ophthalmic)	
GREEN	
1% eye drops BNF @mco	
Amikacin (ophthalmic)	RESTRICTED microbial keratitis.
RED	Consultant Ophthalmologist only
2.5% eye drops BNF emc®	NOT STOCKED
Amphotericin U	RESTRICTED Consultant
RED	Ophthalmologist only
0.15% overdropp	
0.15% eye drops Azithromycin (ophthalmic)	DESTRICTED Consultant
RED CONTROL (Opticialities)	RESTRICTED Consultant Ophthalmologist only
	Opininalinologist only
Azyter ® 1.5% eye drops Ceftazidime (ophthalmic)	DECEDIOTED Consultant
RED	RESTRICTED Consultant
EN IF	Ophthalmologist only
5% eye drops Cefuroxime (ophthalmic)	NOT STOCKED
RED (opntnaimic)	RESTRICTED Consultant
	Ophthalmologist only
5% eye drops BNF emc®	
Cefuroxime (intracameral injection)	RESTRICTED Consultant
Chillie Control	Ophthalmologist only
Ximaract® 50mg in 5mL intracameral injection MMC BNF @mc®	
Chlorhexidine (ophthalmic)	RESTRICTED acanthamoeba
SIAUF En effetos	keratitis. Consultant only
0.02% eye drops BNF @mc®	
Ciprofloxacin (ophthalmic)	RESTRICTED microbial keratitis.
SA	Consultant Ophthalmologist only
0.3% eye drops BNF emc®	
MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour	
MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreve	
MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other thera MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions & precautions for use due to rare reports of disabling & long-	
Erythromycin (ophthalmic)	RESTRICTED superficial eye
RED	infections
0.5% eye ointment BNF emc®	
Gentamicin (ophthalmic)	RESTRICTED Consultant
RED	Ophthalmologist only
4.5% are deeper (Hear with a few prime are deeper)	opinina more gratianity
1.5% eye drops (Use with cefuroxime eye drops) Levofloxacin (ophthalmic)	DECTRICATED Committeest and committees
RED	RESTRICTED Consultant only corneal ulcers/ keratitis
ENT STATE OF THE S	
0.5% eye drops MMC BNF emc MHPA Drug Safety Undate (Sep 23): Elycroguipologe antibiotics: suicidal thoughts and behaviour.	1
MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreve	ersible side effects
MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other thera	
MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions & precautions for use due to rare reports of disabling & long-	·
Natamycin 0	RESTRICTED fungal keratitis,
	conjunctivitis, fungal blepharitis
5% eye drops emc ⊚	
Ofloxacin	RESTRICTED Consultant
RED	Ophthalmologist only
0.3% eye drops MMC BNF @mc	
MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour	
MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreve	
MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other thera	
MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions & precautions for use due to rare reports of disabling & long-	
Penicillin (ophthalmic)	RESTRICTED microbial keratitis.
SAUF Extens	Consultant Ophthalmologist only
2,500 units/mL eye drops BNF emc O	
Polyhexamethylene biguanide (PHMB)	
0.02% eye drops BNF emc®	NOT STOCKED

Propamidine isetionate ①	RESTRICTED Consultant
	Ophthalmologist only
0.1% eye drops	BNF emco
Vancomycin (ophthalmic) U	RESTRICTED gram positives
RED	including MRSA but not VRE
5% eye drops	BNF emc NOT STOCKED
11.3.3 Antivirals	
Ganciclovir	
SI	ESIN P
0.15% eye gel	BNF emc
Trifluorothymidine U	
RED	Ex dilate on
1% eye drops	BNF emc








Section 11 Eye

11.7 Local anaesthetics	Gw <mark>w</mark> wG
Ocular Local anaesthetics	
Fluorescein with lidocaine (minims)	
RED	BNF
4% / 0.25% eye drops	BNF emco
Oxybuprocaine hydrochloride (minims)	
RED	BNF
0.4% eye drops	BNF emc
Proxymetacaine hydrochloride (minims)	
RED	BNF
0.5% eye drops	BNF emc
Tetracaine (Amethocaine) (minims)	
RED	BNF
1% & 2% eve drops	RNE emco



Section 11

Ocular diagnostic preparations				
Fluorescein sodium				
RED		BNF		
% & 2% preservative free eye drops		BNF	emc _®	
Fluorescein sodium				RESTRICTED
RED		(B)N(F		Specialist use only
100mg/mL injection		MMC BNF	emc⊛	fundus fluorescein angiography
Indocyanine green (ICG)				RESTRICTED
RED				Specialist use only
/erdye ® 5mg/mL injection		MMC	emc _®	
Ocular peri-operative drugs				
Acetylcholine chloride				RESTRICTED Consultant
		(B)N(B)		Ophthalmologist only
% intraocular irrigation		BNF	emc _®	
Apraclonidine				RESTRICTED Consultant
SI RED		[B]N][5		Ophthalmologist only
opidine® 0.5% eye drops; 1% preservative free eye drops		BNF	emc _®	
Bromfenac				RESTRICTED Consultant only for
				pseudophakic CMO
Yellox® 0.9 mg/mL eye drops		MMC BNF	<u>emc</u> ⊕	
Ketorolac trometamol				RESTRICTED Consultant
RED				Ophthalmologist only
Acular® 0.5% eye drops		6r children	emc _®	
Nepafenac			(RESTRICTED. 1 st line post catarac
				surgery in diabetics. 2 nd line CMO
Nevanac® 1 mg/mL eye drops		MMC BNF	emc.	
Povidone-lodine			<u> </u>	RESTRICTED Consultant
		티었었		Ophthalmologist only
5% eye drops		MMC BNF	emc@	
Heavy Silicone oil		1011010	Cinco	RESTRICTED intraocular tamponad
•				of inferior retinal breaks
Densiron® 68 - 10mL syringe		MMC		
Subfoveal choroidal neovascularisation				
Aflibercept				RESTRICTED Consultant
RED EE				Ophthalmologist only
Eylea® 40mg in 1mL injection	PbR X NICE	MMC BNF	@mc@	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Bevacizumab U	TURK A TRIBLE		CITIC	RESTRICTED Consultant
RED EE			hluotoa	Ophthalmologist only
A <i>vastin</i> ® 100mg in 4mL vial	PbR X	MMC BNF	blueteq	
Bevacizumab gamma	PDRX		CITIC	RESTRICTED Consultant
RED EE				Ophthalmologist only
Litara (a @ 25 mg/ml injection	DLD V NIOT	MARAO	-	opninal molegist strij
Lytenava® 25 mg/mL injection Brolucizumab	PBR X NICE	MMC BNF	emc	RESTRICTED Consultant
RED (££)				Ophthalmologist only
				Ophthalmologist only
Beovu ® 120mg in 1mL injection VHRA Drug Safety Update (Jan-22): Brolucizumab (Beovu▼): risk of intraocular inflam		MMC BNF		d with chart design intervals
Faricimab	imation and retina	ii vasculai occiusio	i increase	RESTRICTED Consultant
RED (ff)				Ophthalmologist in line with NICE
Jahrana @ 420 mg/ml injection		84840	-	TA799 / TA800 / TA1004
<i>√abysmo</i> ® 120mg/mL injection Ranibizumab	PBR X NICE	MMC BNF	<u>emc⊕</u>	
RED ££				RESTRICTED Consultant
 •				Ophthalmologist only
Lucentis® / Ongavia® 10mg/mL injection	PbR X NICE	MMC BNF	emc _®	Eng.
Verteporfin RED (EE)				RESTRICTED Consultant
				Ophthalmologist only
//isudyne® 15mg vial	PbR X	MMC BNF	emc _®	
Vitreomacular traction				
44.0.2.04h				
11.8.3 Other preparations				
Voretigene				
Voretigene neparvovec				RESTRICTED Consultant
NED ***			blueteq	Ophthalmologist in line with NICE
	PbR X NICE	MMC	emc _®	
Luxturna® 2mL vial Insulin eye drops				
Insulin eye drops Insulin (soluble) eye drops				RESTRICTED
Insulin eye drops				RESTRICTED Consultant Ophthalmologist

Kimmtrak® 200micrograms/mL infusion

		-,,
Non-Formulary Items		GM <mark>M</mark> MG
Cenegermin		DISCONTINUED January 2020
Oxervate®	NICE	
Commercial eyelid cleansing preparations (DNP)		in line with GMMMG
		Criterion 1
Conjunctivitis (bacterial) (DNP)		in line with GMMMG / NHSE
Chloramphenicol eye drops or ointment.		
Conjunctivitis (viral) (DNP)		in line with GMMMG / NHSE
Hypromellose eye drops		
Dry eyes / sore tired eyes (DNP)		in line with GMMMG / NHSE
Hypromellose eye drops, carbomer 980 gel, hyaluronate eye drops		
Ocriplasmin RED (f)		DISCONTINUED May 2020
Jetrea® 0.5mg/0.2mL injection	PBRX NICE MMC BNF emc	
Polymyxin B sulfate		DISCONTINUED November 2017
Polyfax® eye ointment	BNF emco	
Poly (carboxymethylglucose sulfate)		DISCONTINUED December 2019
Cacicol® eye drops (0.33mL)	MMC BNF emco	
Simple eye ointment (DNP)		in line with GMMMG
	BNF emco	Criterion 1
Tebentafusp Red EE		NOT STOCKED. Patients treated at commissioned centre in Liverpool

PBRX NICE MMC BNF emco

Section 12: Ear, nose & oropharynx

Supported by the formulary (click here



- 12.1 Drugs acting on the ear
 - 12.1.1 Otitis externa
 - 12.1.3 Removal of ear wax
- 12.2 Drugs acting on the nose
 - 12.2.1 Drugs used in nasal allergy
 - 12.2.2 Topical nasal decongestants
 - 12.2.3 Nasal preparations for infection
- 12.3 Drugs acting on the oropharynx
 - 12.3.1 Drugs for oral ulceration & inflammation
 - 12.3.2 Oropharyngeal anti-infective drugs
 - 12.3.4 Mouthwashes, gargles & dentifrices
 - 12.3.5 Treatment of dry mouth

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)
PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)
Non-formulary Conversion Table

NICE Guidance

Sinusitis (acute): antimicrobial prescribing (NG79) Sore throat (acute): antimicrobial prescribing (NG84) Otitis media (acute): antimicrobial prescribing (NG91) Tinnitus: assessment and management (NG155) Otitis media with effusion in under 12s (NG233)


Allergic rhinitis (CKS)

GMMMG Formulary


Formulary Homepage

Chapter 12: Ear, nose & oropharynx

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List







Non-Formulary Items	GMMG
Acute sore throat (DNP)	in line with GMMMG
Fore throat lozenges and sprays, analgesics	
Coughs, colds and nasal congestion (DNP)	in line with GMMMG
Pseudoephedrine nasal sprays and oral preparations. Xylometazoline and ephedrine nasal sprays and drops	
Ear wax removal (DNP)	in line with GMMMG
Dlive oil, sodium bicarbonate ear drops. Includes prior to syringing	
Mouth ulcers (DNP)	in line with GMMMG
ocal anaesthetic gels, hydrocotrisone buccal tablets	
Oral thrush (DNP)	in line with GMMMG
liconazole oral gel, nystatin oral suspension	

Section 13: Skin

Supported by the formulary (click here)



- 13.2 Emollient & barrier preparations
 - 13.2.1 Emollients
 - 13.2.2 Barrier preparations
- 13.3 Topical local anaesthetics & antipruritics
- 13.4 Topical corticosteroids
- 13.5 Preparations for eczema & psoriasis
 - 13.5.1 Preparations for eczema
 - 13.5.2 Preparations for psoriasis
 - 13.5.3 Drugs affecting the immune response Cytokine Modulators
- 13.6 Acne & Rosacea
 - 13.6.1 Topical preparations for acne
 - 13.6.2 Oral preparations for acne
- 13.7 Preparations for warts & calluses
- 13.8 Sunscreens & camouflagers
 - 13.8.1 Sunscreen preparations
- 13.9 Shampoos & other preparations for scalp/hair conditions
- 13.10 Anti-infective skin preparations
 - 13.10.1 Antibacterial preparations
 - 13.10.2 Antifungal preparations
 - 13.10.3 Antiviral preparations
 - 13.10.4 Parasiticidal preparations
 - 13.10.5 Preparations for minor cuts & abrasions
- 13.11 Skin cleansers, antiseptics & desloughing agents
 - 13.11.1 Alcohols & saline
 - 13.11.2 Chlorhexidine salts
 - 13.11.4 lodine
 - 13.11.6 Oxidisers & dyes
 - 13.11.7 Desloughing agents
- 13.12 Antiperspirants
- 13.13 Topical circulatory preparations
- 13.14 Miscellaneous preparations
- Non-Formulary Items

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Biosimilar Medicines (KTT15)

Atopic eczema in children (CG57)

Psoriasis: assessment and management (CG153)

Pressure Ulcers (CG179)

Pubic lice CKS (2011)

Scabies CKS (2011)

Acne vulgaris CKS (2014)

Head lice CKS (2015)

Surgical site infections: prevention and treatment (NG125)

Atopic dermatitis (eczema) - topical steroids (TA81)

Atopic dermatitis (eczema) - pimecrolimus and tacrolimus (TA82)

Psoriasis - efalizumab and etanercept (TA103)

Psoriasis - infliximab (TA134)

Psoriasis - adalimumab (TA146)

Alitretinoin for the treatment of severe chronic hand eczema (TA177)

Psoriasis - ustekinumab (TA180)

Melanoma (stage III or IV) - ipilimumab (TA268)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib (TA269)

Ustekinumab for treating active psoriatic arthritis (rapid review of TA313) (TA340)

Secukinumab for treating moderate to severe plaque psoriasis (TA350)

Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)

Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)

Apremilast for treating moderate to severe plaque psoriasis (replaces TA368) (TA419)

Apremilast for treating active psoriatic arthritis (TA433)

Ixekizumab for treating moderate to severe plaque psoriasis (TA442)

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)

Dimethyl fumarate for treating moderate to severe plague psoriasis (TA475)

Brodalumab for treating moderate to severe plaque psoriasis (TA511)

Guselkumab for treating moderate to severe plague psoriasis (TA521)

Dupilumab for treating moderate to severe atopic dermatitis (TA534)

Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)

Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)

Risankizumab for treating moderate to severe plaque psoriasis (TA596)

Baricitinib for treating moderate to severe atopic dermatitis (TA681)

Secukinumab for treating moderate to severe plague psoriasis in children and young people (TA734)

Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)

Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (TA814)

Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)

Difelikefalin for treating pruritus in people having haemodialysis (TA890)

Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)

Bimekizumab for treating active psoriatic arthritis (TA916)

Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)

Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (TA950)

Ritlecitinib for treating severe alopecia areata in people 12 years and over (TA958)

Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA986)

GMMMG Formulary


Formulary Homepage


Chapter 13: Skin

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List

EMA (efalizumab)





13.4 Topical corticosteroids GMMMGCorticosteroid only preparations NICE TA81 MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration **HYDROCORTISONE Potency** Canesten HC® Mild GREEN hydrocortisone 1% plus clotrimazole 1% cream BNF emce Daktacort® Mild hydrocortisone 1%, miconazole nitrate 2% cream; ointment BNF emc Eurax-hydrocortisone® Mild hydrocortisone 0.25%, crotamiton 10% cream BNF emc® Fucidin H® Mild GREEN hydrocortisone 1%, fusidic acid 1% cream BNF emc Terra-Cortril® Mild hydrocortisone 1%, oxytetracycline 3% ointment BNF emc **BETAMETHASONE ESTERS Potency** MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions Betamethasone valerate Moderate GREEN betamethasone valerate 0.025% ointment, cream BNF emc Betnovate-RD® Moderate GREEN betamethasone valerate 0.025% cream: ointment BNF emc **CLOBETASONE BUTYRATE Potency** MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions **Eumovate**® **Moderate** Clobetasone butvrate 0.05% cream: ointment BNF emc **BETAMETHASONE ESTERS Potency** MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions Betamethasone valerate **Potent** GREEN betamethasone valerate 0.1% ointment; cream; lotion; scalp lotion BNF emc Betnovate® **Potent** GREEN Betamethasone valerate 0.1% cream; ointment; scalp application; lotion BNF emc Betamethasone valerate with clioquinol **Potent** BNF emc betamethasone valerate 0.1% / clioquinol 3% ointment; cream Betamethasone valerate with neomycin sulfate Potent betamethasone valerate 0.1% / neomycin sulfate 0.5% cream; ointment BNF emc® Diprosalic ® Potent Betamethasone dipropionate 0.05%, salicylic acid 3% ointment BNF emc Fucibet® **Potent** GREEN betamethasone valerate 0.1% plus fusidic acid 2% cream BNF emc Betnovate® Potent

betamethasone valerate ointment 25% in coal tar


DERMATOLOGY ONLY


CLOBETASOL PROPIONATE		Potency
MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, I	reminder of possible severe side effects, including v	withdrawal reactions
MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk	of topical steroid withdrawal reactions	
Dermovate ®		
GREEN		Very potent
clobetasol propionate 0.05% ointment; cream; lotion; scalp lotion	BNF emco	
Dermovate NN®		
		Very potent
clobetasol propionate 0.05% / neomycin sulfate / nystatin cream	BNF emco	
Etrivex®	<u> </u>	
GREEN		Very potent
clobetasol propionate 500micrograms/g shampoo	MMO	RESTRICTED - 1 ^{ry} Care referral
	MMC BNF emc	
DIFLUCORTOLONE VALERATE		Potency
Diflucortolone valerate 0		V
		Very potent
diflucortolone valerate 0.3% oily cream	MMC emc	RESTRICTED Consultant Gynaecologist

13.5 Preparations for eczema & psoriasis GMMMG13.5.1 Preparations for eczema Alitretinoin **RESTRICTED Dermatology Consultants only** 10mg; 30mg capsules PBRX NICE MMC BNF CMC MHRA Drug Safety Update (Jul-21): Oral retinoid medicines (isotretinoin ▼, alitretinoin ▼ & acitretin ▼): temporary monitoring advice during COVID-19 pandemic MHRA Drug Safety Update (Jun-19): Oral retinoid medicines ▼: revised and simplified pregnancy prevention educational materials for healthcare professionals & women 13.5.2 Preparations for psoriasis Topical preparations for psoriasis NICE CG153 Calcipotriol RESTRICTED GREEN **Dermatology Consultants only** Dovonex® ointment: with Betamethasone (Dovobet® 0.05% ointment) BNF emc® **Dithranol RESTRICTED Dermatology Consultants only** Dithocream ® 0.1% & 0.25% cream BNF emc Salicylic acid **RESTRICTED Dermatology Consultants only** Zinc & Salicylic acid paste BP (Lassar's Paste) BNF emc **Tacalcitol** RESTRICTED **Dermatology Consultants only** Curatoderm® lotion: ointment BNF emc Tars Coal tar paste BP RESTRICTED **Dermatology Consultants only** BNF emc Coal tar with salicylic acid and precipitated sulfur RESTRICTED **Dermatology Consultants only** Cocois® scalp ointment BNF emc Oral retinoids for psoriasis Acitretin **RESTRICTED** RED **Dermatology Consultants only** 10mg; 25mg capsules BNF emc Dimethyl fumarate **Dimethyl fumarate** RESTRICTED RED ££ 3rd/4th line as per NICE/GMMMG blueteq **Referral to SRFT** 30mg; 120mg tablets PBR X NICE MMC BNF emc 13.5.3 Drugs affecting the immune response **Abrocitinib RESTRICTED Dermatology Consultants only** blueteq in line with NICE Cibingo ® 50mg; 100mg; 200mg tablets PBRX NICE MMC BNF @MC® MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections and increased mortality **Azathioprine RESTRICTED Dermatology Consultants only** 25mg; 50mg tablets (see also sections 1.5.3, 8.2.1 & 10.1.3) PbR X NICE BNF emc® MHRA Drug Safety Update (May-25): Thiopurines and intrahepatic cholestasis of pregnancy Ciclosporin **RESTRICTED Dermatology Consultants only PRESCRIBE BY BRAND** 25mg, 50mg & 100mg caps; 100mg/1mL oral soln; Infusion (see also section 8.2.2) PbR X MMC BNF emc® Methotrexate RESTRICTED **Dermatology Consultants only** 2.5mg tablets (see also sections 8.1.3 & 10.1.3) MMC BNF emc **Pimecrolimus RESTRICTED Dermatology Consultants only** % cream NICE MMC BNF emc **Sirolimus RESTRICTED Dermatology Consultants only** Hyftor® 0.2% gel (see also section 8.2.2) MMC BNF emc Tacrolimus (specially made by SRFT) RESTRICTED **Dermatology Consultants only** 0.03%; 0.1% ointment (see also section 8.2.2) PBRX NICE MMC BNF CMC Upadacitinib **RESTRICTED** RED EE **Dermatology Consultants only** blueteq in line with NICE Rinvoq® 15mg; 30mg MR tablets (see also sections 1.5.3 & 10.1.3) PBRX NICE MMC BNF emc


MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections and increased mortality


Skin






MHRA Drug Safety Update (Dec-14): Isotretinoin (Roaccutane): reminder of possible risk of psychiatric disorders









13.10 Anti-infective skin preparations GM<mark>M</mark>MG 13.10.1 Antibacterial preparations Topical antibacterials should generally be avoided for the treatment of infections 13.10.1.1 Antibacterial preparations only used topically Mupirocin 2% cream; ointment MMC BNF emc Fusidic acid **RESTRICTED** superficial impetigo 2% cream: ointment BNF emc Metronidazole RESTRICTED GREEN topical treatment of rosacea 0.75% topical gel; cream BNF emc® Silver sulfadiazine **RESTRICTED** GREEN Treatment/prophylaxis of burns 1% w/w cream BNF emc 13.10.2 Antifungal preparations **Amorolfine** 1st line antifungal for nail infections 5% nail lacquer MMC BNF emc® Benzoic acid with salicylic acid 1st line treatment of ringworm benzoic acid 6% / salicylic acid 3% / in emulsifying ointment BNF emc Clotrimazole 1st line GREEN fungal skin infections 1% cream BNF emc Miconazole 2nd line GREEN OTC fungal skin infections BNF emc 2% cream Terbinafine 2nd line GREEN OTC fungal skin infections 1% cream BNF emc 13.10.3 Antiviral preparations Aciclovir 1st line GREEN OTC 5% cream (see also section 5.3.2.1) BNF emc 13.10.4 Parasiticidal preparations NICE CKS: Head lice NICE CKS: Pubic lice **NICE CKS: Scabies** Ivermectin (1) MMC BNF emc® Malathion 0.5% aqueous solution BNF emc Permethrin GREEN BNF emc MHRA Drug Safety Update (Mar-18): Head lice eradication products: risk of serious burns if treated hair is exposed to open flames or other sources of ignition. 13.10.5 Preparations for minor cuts & abrasions **Brulidine RESTRICTED** Theatres only 0.15% w/w cream emc_® Preparations for boils Magnesium sulfate naste RP BNF emc® Skin tissue adhesive Histoacryl® **RESTRICTED** Theatres only

0.5mL skin adhesive

BNF emc®





13.13 Topical circulatory preparations Topical circulatory preparations Heparinoid Hirudoid ® 0.3% cream; 0.3% gel ■NF emc

13.14 Miscellaneous preparations				G⋈ <mark>M</mark> MG	
8-Methoxypsoralen				RESTRICTED Dermatology Consultants only	y
10mg tablets		MMC	emc _®		
Fumaric acid esters				RESTRICTED Dermatology Consultants only	 У
Fumaderm® tablets		MMC	emc _®		
Glucarpidase 🕕				RESTRICTED	
		[8]		2 nd line rescue therapy	
Voraxaze® 1,000 unit injection (see also sections 1.10, 8.4 & 10.4)	PbR X	MMC 🔠	NF emc		NHS England
Hyaluronic acid with lidocaine 🄱				RESTRICTED	
				vocal cord paralysis	
Juvederm® / Belotero® injection		MMC	emc _®		

Ringworm / Athlete's foot	in line with GMMMG / NHSE
(DNP) OTC	III IIIIE WILLI GMMIMG / NITSE
Topical preparations containing miconazole, clotrimazole, etc	
Silk garments	in line with GMMMG / NHSE
(DNP)	III lille with Gmmmg / NH3E
including Dermasilk®, Dreamskin®, Skinnies Silk®	
Sun protection	in line with GMMMG / NHSE
(DNP) OTC	In line with GMMMG / NHSE
Sunburn due to excessive sun exposure	to the south Chillian
(DNP) OTC	in line with GMMMG / NHSE
E.g. emollients, oral and topical antihistamines, analgesics	
Warts and verrucae	
(DNP) OTC	in line with GMMMG / NHSE
Salicylic acid-containing products, glutaraldehyde	

Section 14: Immunological products & vaccines | Supported by the formulary (click here)



14.4 Vaccines & antisera

Bacillus Calmette-Guérin (BCG) vaccines

Botulism antitoxin

COVID-19 vaccine

Diphtheria vaccines (children under 10yrs old)

Diphtheria vaccines (children over 10yrs old & adults)

Haemophilus type B conjugate vaccine

Hepatitis A vaccine

Hepatitis B vaccine

Human papilloma virus vaccine

Influenza vaccine

Measles, Mumps & Rubella (MMR) vaccine

Meningococcal vaccines

Pneumococcal vaccines

Poliomyelitis vaccines

Rabies vaccines

Respiratory syncytial virus (RSV) vaccine

Tetanus vaccines

Typhoid vaccines

Varicella-zoster vaccines

14.5 Immunoglobulins

14.5.1 Normal immunoglobulin

14.5.2 Disease-specific immunoglobulins

14.5.3 Anti-D (Rh₀) immunoglobulin

Non-Formulary Items

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Guidelines for the Prescribing and Administration of Intravenous Immunoglobulin

Immunoglobulin follow up form

Immunoglobulin Prescribing and Administration Guidelines

Immunoglobulin Prescribing Flow Chart

Immunoglobulin request form

National Demand Programme for Immunoglobulin - Clinical Info

Non-formulary Conversion Table

NICE Guidance

Pregnancy - routine anti-D prophylaxis for rhesus negative women (TA156)

GMMMG Formulary

Formulary Homepage

Chapter 14: Immunological products & vaccines

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List


Other Links

National Immunoglobulin Database

DH: Clinical guidelines for immunoglobulin use (2nd edition update)

Immunoglobulin handbook (HPA)

14.4 Vaccines & antisera		GMMMG
MHRA Drug Safety Update (Apr-16): Live attenuated vaccines: avoid use in those who are clinically immunos	suppressed	
Bacillus Calmette-Guérin (BCG) vaccines		Tuberculosis: the Green Book, ch.32
Bacillus Calmette-Guérin (BCG) vaccine		
injection	BNF emco	
BCG vaccine diagnostic agent (Tuberculin purified protein derivative (PPD))	<u> </u>	
injection	PNE OMCO	
Botulism antitoxin	BNF emc	4
Botulism antitoxin		RESTRICTED
	CHINDS .	Emergencies only
	(5)IN.IP for children	Emergencies only
injection	BNF emc	CaviddOr Aba Cream Baalt, ab 44a
COVID-19 vaccine		Covid19: the Green Book, ch.14a
Pfizer-BioNTech COVID-19 vaccine (Tozinameran / Famtozinameran)		12 years of age and older
	BING for children	
Comirnaty® Original/Omicron BA.4-5 (15/15 micrograms)/dose (GREY cap)	BNF emc	pending availability of XBB1.5
Pfizer-BioNTech COVID-19 vaccine (Raxtozinameran)		12 years of age and older
	BNF	j ca. o or ago arra oraci
Comirnaty® Omicron XBB.1.5 - 30micrograms/dose injection (GREY cap)	BNF emc	
Pfizer-BioNTech COVID-19 vaccine (Raxtozinameran)		5 to 11 year olds
		5 to 11 year olds
Comirnaty® Omicron XBB.1.5 - 10micrograms/dose injection (BLUE cap)	BNF emc	
MHRA Drug Safety Update (Mar-23): COVID-19 vaccines: updates for March 2023		
MHRA Drug Safety Update (Feb-23): COVID-19 vaccines: updates for February 2023		
MHRA Drug Safety Update (Jan-23): COVID-19 vaccines: updates for January 2023		
MHRA Drug Safety Update (Dec-22): COVID-19 vaccines: updates for December 2022		
MHRA Drug Safety Update (Nov-22): COVID-19 vaccines: updates for November 2022		
MHRA Drug Safety Update (Oct-22): COVID-19 vaccines: updates for October 2022 MHRA Drug Safety Update (Sep-22): COVID-19 vaccines: updates for September 2022		
MHRA Drug Safety Update (Aug-22): COVID-19 vaccines: updates for August 2022		
MHRA Drug Safety Update (Jul-22): COVID-19 vaccines: updates for July 2022		
MHRA Drug Safety Update (Jun-22): COVID-19 vaccines: updates for June 2022		
MHRA Drug Safety Update (May-22): COVID-19 vaccines: updates for May 2022		
MHRA Drug Safety Update (Apr-22): COVID-19 vaccines: updates for April 2022		
MHRA Drug Safety Update (Mar-22): COVID-19 vaccines: updates for March 2022		
MHRA Drug Safety Update (Feb-22): COVID-19 vaccines: updates for February 2022 MHRA Drug Safety Update (Jan-22): COVID-19 vaccines: updates for January 2022		
MHRA Drug Safety Update (Dec-21): COVID-19 vaccines: updates for December 2021		
MHRA Drug Safety Update (Nov-21): COVID-19 vaccines: updates for November 2021		
MHRA Drug Safety Update (Oct-21): COVID-19 vaccines: updates for October 2021		
MHRA Drug Safety Update (Sep-21): COVID-19 vaccines: updates for September 2021		
MHRA Drug Safety Update (Aug-21): COVID-19 vaccines: updates for August 2021		
MHRA Drug Safety Update (Jul-21): COVID-19 vaccines: updates for July 2021		
MHRA Drug Safety Update (Jun-21): COVID-19 vaccines: updates for June 2021 MHRA Drug Safety Update (May-21): COVID-19 vaccines: updates for May 2021		
MHRA Drug Safety Update (Feb-21): COVID-19 vaccines and medicines: updates for February 2021		
MHRA Drug Safety Update (Jan-21): COVID-19 vaccines (Pfizer/BioNTech and COVID-19 Vaccine AstraZer	neca): current advice	
MHRA (Dec-20): Regulatory approval of Pfizer/BioNTech vaccine for COVID-19		
Diphtheria vaccines (children under 10yrs old)		Diptheria: the Green Book, ch.15
Infanrix hexa®		
	[8][8]	
injection	BNF emc	
Infanrix-IPV®		
injection	BNF emco	
Repevax®	EIIIC	7
T	e)N(e.	
injection	(CO) Num for children	
injection Diphthoria vaccines (children ever 10 yrs old 1 adults)	BNF emc	Dinthorio: the Green Beak, sh.45
Diphtheria vaccines (children over 10yrs old & adults)		Diptheria: the Green Book, ch.15
Revaxis®		
	(S)NUS for shildren	
injection	BNF emc	



14.5 Immunoglobulins



- **1.)** All Immunoglobulin requests should follow NHSE Clinical Commissioning Policy for the use of therapeutic immunoglobulin (Ig) England (2024).
- **2.)** MFT have adopted a 'no form, no immunoglobulin' policy. All IVIg requests must have an Immunoglobulin Request Form completed via Hive.
- 3.) All immunoglobulin use MUST be recorded on the National Immunoglobulin Database.

14.5.1 Normal immunoglobulin RED	(for ITP & home treatment programmes)	GMMG
For intramuscular use		
Normal immunoglobulin injection		RESTRICTED Specialist use only
injection	PbR X BNF @MC®	
For subcutaneous use		
Normal immunoglobulin injection RED	PBRX MMC BNF (emcs)	RESTRICTED Specialist use only
For intravenous use	WIMO BIT GITCS	
Human normal immunoglobulin	PBRX MMC BNF (emco	RESTRICTED Specialist use only
injection 14.5.2 Disease-specific immunoglobulins	PbR X) MMC BNF emc	GM <mark>M</mark> MG
		GMMMG
Hepatitis B immunoglobulin		
Hepatitis B immunoglobulin	BNF (emco	RESTRICTED Not Stocked
Tetanus immunoglobulin	SM SINGS	
Tetanus immunoglobulin	BNF (emco	
Varicella-Zoster immunoglobulin		
Varicella-Zoster immunoglobulin GREEN injection	BNF emco	RESTRICTED Not Stocked
Cytomegalovirus (CMV) immunoglobulin		
Human normal immunoglobulin (CMV)	INVE	RESTRICTED Specialist use only
injection	MMC BNF emco	-
14.5.3 Anti-D (Rh ₀) immunoglobulin		GM <mark>M</mark> MG
Anti-D (Rh₀) immunoglobulin		
RED injection	NICE MMC BNF @mc@	

Non-Formulary Items	Gw <mark>w</mark> wG
AstraZeneca COVID-19 vaccine	DISCONTINUED May 2024
Vaxzevria® injection	MMC BNF emco
Moderna Biotech COVID-19 vaccine	DISCONTINUED
Spikevax® injection	MMC BNF emco
Novavax COVID-19 vaccine	PAUSED by JCVI
Nuvaxovid® injection	MMC BNF emco
Pediacel®	REPLACED by
injection	Infanrix hexa®
Infanrix-IPV+Hib®	BNF emco
IIIIaiiiia-ir V Tiiij w	REPLACED by
	Infanrix hexa®
injection	BNF emco

Section 15: Anaesthesia

Supported by the formulary (click here)



15.1 General anaesthesia

15.1.1 Intravenous anaesthetics

15.1.2 Inhalational anaesthetics

15.1.3 Antimuscarinic drugs

15.1.4 Sedative & analgesic post-operative drugs

15.1.4.1 Benzodiazepines

15.1.4.2 Non-opioid analgesics

15.1.4.3 Opioid analgesics

15.1.4.4 Other drugs for sedation

15.1.5 Neuromuscular blocking drugs

Non-depolarising neuromuscular blocking drugs

Depolarising neuromuscular blocking drugs

15.1.6 Drugs for reversal of neuromuscular blockade

Anticholinesterases

Other drugs for reversal of neuromuscular blockade

15.1.7 Antagonists for central & respiratory depression

15.1.8 Drugs for malignant hyperthermia

15.2 Local anaesthesia

Lidocaine

Bupivacaine

Levobupivacaine

Prilocaine

Ropivacaine

Tetracaine

Local Anaesthetic Toxicity

Other agents

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Paediatric Anaesthesia Website

Children's Pain Management Website

PICU Emergency Drugs Calculator

Non-formulary Conversion Table

NICE Guidance

Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)


GMMMG Formulary


Formulary Homepage


Chapter 15: Anaesthesia (ON HOLD)

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List







Section 16: Miscellaneous



16.1 Organ Perfusion Fluids

- 16.1.1 Cardiac Perfusion Fluids 16.1.2 Kidney / Pancreas / Liver perfusion fluids
- 16.1.3 Contrast Agents
- 16.1.4 Hydrogen / Methane breath tests
- 16.1.5 Catheter Lock Solution

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)
NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Machine perfusion systems and cold static storage of kidneys from deceased donors (TA165)

GMMMG Formulary

Formulary Homepage

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List
GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List

16.1 Organ Perfusion fluids		
16.1.1 Cardiac perfusion fluids		
Aspartate / Glutamate solution ①		
100mL	MMC	
Bretschneiders Histidine-Trytophan-Ketoglutarate (HTK)		
Diotominate in installine Trytophan Rotogiatarate (TTTT)		
0. (4000.1)	88880	
Custodiol Cardioplegia® solution (1000mL) Cardioplegia in Ringer's solution U	MMC emo	(<u>(</u>)
Cardiopiegia in Milger's Solution		
1000mL	MMC em	•
Cardioplegic ULTH Formula A 0		
500mL	MMC	
Cardioplegic ULTH Formula B		
500mL	MMC	
Sterile Concentrate for Cardioplegia infusion		
20mL	MMC emo	30
16.1.2 Kidney / Pancreas / Liver perfusion fluids		
Cold Storage Solution (UW solution)		
Belzer UW® (1000mL)	MMC	
Kidney Perfusion Fluid		
Soltran® (1000mL)	MMC	
Lung Perfusion solution		
Perfadex® (1000mL)	MMC	
Machine Perfusion solution		
madimid i diradidii ddiadidii		
D./MD0010M	8484	
Belzer MPS® UW machine perfusion solution (1000mL) 16.1.3 Contrast Agents	MMC	
Gadobutrol		
Gadovist ® (1.0mmol/mL) injection	BABAO	
Gadoteric acid	MMC emo	
Cadotono dola		
Date was 0 (0 Francishal) in the	24240	
Dotarem ® (0.5mmol/mL) injection Gadoxetic acid	MMC emo	(a)
Gaudaette acid		
Primovist ® (0.25mmol/mL) injection	MMC emo	(1)
Perflutren		
Luminity ® (150microlitres/mL) lipid microspheres for injection	MMC emo	0
Sulphur hexafluoride		
SonoVue ® (8microlitre/mL) injection	MMC emo	0
16.1.4 Hydrogen / Methane breath tests		
Fructose, Glucose, Lactose and Lactulose		RESTRICTED Gastro. only in line with
	≢ ESPGH	ESPGHAN guidelines
powder	MMC emo	(a)
16.1.5 Catheter Locking Solution		
Tetrasodium ethylene diamine tetra acetic acid (EDTA)		
KiteLock™ 4% sterile catheter lock solution	MMC emo	(a)
Trisodium citrate 30%		
Citra-Lock™ 30%	MMC emo	0